Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Dec. 31, 2023	Feb. 22, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Trading Symbol	OLED
Entity Registrant Name	UNIVERSAL DISPLAY CORPORATION
Document Financial Statement Error Correction [Flag]	false
Entity Central Index Key	0001005284
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	PA
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	1-12031
Entity Tax Identification Number	23-2372688
Entity Address, Address Line One	250 Phillips Boulevard
Entity Address, City or Town	Ewing
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08618
City Area Code	609
Local Phone Number	671-0980
Entity Common Stock, Shares Outstanding		47,365,600
Entity Public Float			$ 320,500,461
ICFR Auditor Attestation Flag	true
Documents Incorporated by Reference	Portions of the registrant’s Proxy Statement for the 2024 Annual Meeting of Shareholders, which is to be filed with the Securities and Exchange Commission no later than April 29, 2024 (the first business day after the 120th day following the end of the registrant's fiscal year), are incorporated by reference into Part III of this report.
Auditor Firm ID	185
Auditor Name	KPMG, LLP
Auditor Location	Philadelphia, PA, USA

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

CURRENT ASSETS:

Cash and cash equivalents

$ 91,985

$ 93,430

Short-term investments

422,137

484,345

Accounts receivable

139,850

92,664

Inventory

175,795

183,220

Other current assets

87,365

45,791

Total current assets

917,132

899,450

PROPERTY AND EQUIPMENT, net of accumulated depreciation of $143,908 and $117,118

175,150

143,445

ACQUIRED TECHNOLOGY, net of accumulated amortization of $186,850 and $189,671

90,325

^[1]

38,382

OTHER INTANGIBLE ASSETS, net of accumulated amortization of $10,414 and $8,989

6,874

8,247

GOODWILL

15,535

INVESTMENTS

299,548

259,861

DEFERRED INCOME TAXES

59,108

58,161

OTHER ASSETS

105,289

109,739

TOTAL ASSETS

1,668,961

1,532,820

CURRENT LIABILITIES:

Accounts payable

10,933

9,519

Accrued expenses

52,080

51,002

Deferred revenue

47,713

45,599

Other current liabilities

8,096

29,577

Total current liabilities

118,822

135,697

DEFERRED REVENUE

12,006

18,279

RETIREMENT PLAN BENEFIT LIABILITY

52,249

59,790

OTHER LIABILITIES

38,658

43,685

Total liabilities

221,735

257,451

COMMITMENTS AND CONTINGENCIES (Note 18)

SHAREHOLDERS' EQUITY:

Preferred Stock, par value $0.01 per share, 5,000,000 shares authorized, 200,000 shares of Series A Nonconvertible Preferred Stock issued and outstanding (liquidation value of $7.50 per share or $1,500)

2

Common Stock, par value $0.01 per share, 200,000,000 shares authorized, 48,731,026and 49,136,030 shares issued, and 47,365,378 and 47,770,382 share outstanding at December 31, 2023 and December 31, 2022, respectively

487

491

Additional paid-in capital

699,554

681,335

Retained earnings

789,553

653,277

Accumulated other comprehensive loss

(1,086)

(18,452)

Treasury stock, at cost (1,365,648 shares at December 31, 2023 and December 31, 2022)

(41,284)

Total shareholders’ equity

1,447,226

1,275,369

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 1,668,961

$ 1,532,820

[1]	During the year ended December 31, 2023, the gross value and accumulated amortization associated with the PD-LD, Inc. and Motorola patent portfolios have been removed from the table as the underlying patents have reached the end of their useful lives.

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment

$ 143,908

$ 117,118

Finite-Lived Intangible Assets, Accumulated Amortization

186,850

^[1]

189,671

Other Finite-Lived Intangible Assets, Accumulated Amortization

$ 10,414

$ 8,989

SHAREHOLDERS' EQUITY:

Preferred Stock, par value (in dollars per share)

$ 0.01

Preferred Stock, shares authorized ( in shares)

5,000,000

Common Stock, par value (in dollars per share)

$ 0.01

Common Stock, shares authorized (in shares)

200,000,000

Common Stock, shares issued (in shares)

48,731,026

49,136,030

Common Stock, shares outstanding (in shares)

47,365,378

47,770,382

Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]

Treasury Stock, Common, Shares

1,365,648

Treasury Stock, Preferred, Shares

1,365,648

Series A Nonconvertible Preferred Stock [Member]

Shareholders' Equity A Nonconvertible Preferred Stock

Preferred Stock, shares issued (in shares)

200,000

Preferred Stock, shares outstanding (in shares)

200,000

Preferred Stock, liquidation value per share (in dollars per share)

$ 7.5

Preferred Stock, liquidation value

$ 1,500

[1]	During the year ended December 31, 2023, the gross value and accumulated amortization associated with the PD-LD, Inc. and Motorola patent portfolios have been removed from the table as the underlying patents have reached the end of their useful lives.

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUE:
Total revenue	$ 576,429	$ 616,619	$ 553,525
COST OF SALES	135,376	127,896	114,991
Gross margin	441,053	488,723	438,534
OPERATING EXPENSES:
Research and development	130,481	117,062	99,673
Selling, general and administrative	67,387	77,886	80,372
Amortization of acquired technology and other intangible assets	15,993	17,459	21,994
Patent costs	9,356	8,329	8,160
Royalty and license expense	647	877	691
Total operating expenses	223,864	221,613	210,890
OPERATING INCOME	217,189	267,110	227,644
Interest income, net	28,166	7,811	505
Other (loss) income, net	(184)	(6,691)	98
Interest and other income, net	27,982	1,120	603
Income before income taxes	245,171	268,230	228,247
INCOME TAX EXPENSE	(42,160)	(58,169)	(44,034)
NET INCOME	$ 203,011	$ 210,061	$ 184,213
NET INCOME PER COMMON SHARE:
BASIC	$ 4.25	$ 4.41	$ 3.87
DILUTED	$ 4.24	$ 4.4	$ 3.87
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:
BASIC	47,559,669	47,390,352	47,296,447
DILUTED	47,622,763	47,468,507	47,365,435
CASH DIVIDEND DECLARED PER COMMON SHARE	$ 1.4	$ 1.2	$ 0.8
Material sales
REVENUE:
Total revenue	$ 322,029	$ 331,081	$ 318,623
Royalty and license fees
REVENUE:
Total revenue	238,389	267,115	219,032
Contract research services
REVENUE:
Total revenue	$ 16,011	$ 18,423	$ 15,870

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
NET INCOME	$ 203,011	$ 210,061	$ 184,213
OTHER COMPREHENSIVEINCOME (LOSS), NET OF TAX:
Unrealized gain (loss) on available-for-sale securities, net of tax of ($351), none and $65, respectively	8,745	(7,745)	(233)
Employee benefit plan:
Actuarial gain on retirement plan, net of tax of ($2,168), ($1,667) and ($1,336), respectively	7,207	5,971	13,620
Plan amendment cost, net of tax of none, none and $79, respectively	0	0	(283)
Amortization of prior service cost and actuarial loss for retirement plan included in net periodic pension costs net of tax of ($299), ($569) and ($1,316), respectively	996	2,037	4,719
Net change in employee benefit plan	8,203	8,008	18,056
Change in cumulative foreign currency translation adjustment	418	(480)	(39)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	17,366	(217)	17,784
COMPREHENSIVE INCOME	$ 220,377	$ 209,844	$ 201,997

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Unrealized gain (loss) on available-for-sale securities, tax	$ (351)	$ 0	$ 65
Actuarial gain on retirement plan, tax	(2,168)	(1,667)	(1,336)
Plan amendment cost	0	0	79
Amortization of prior service cost and actuarial loss for retirement plan included in net periodic pension costs, tax	$ (299)	$ (569)	$ (1,316)

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock, Common [Member]	Series A Nonconvertible Preferred Stock [Member] Preferred Stock [Member]
BALANCE at Dec. 31, 2020	$ 912,714	$ 490	$ 635,595	$ 353,930	$ (36,019)	$ (41,284)	$ 2
BALANCE (in shares) at Dec. 31, 2020		49,013,476				1,365,648	200,000
Net income	184,213			184,213
Other comprehensive income (loss)	17,784				17,784
Cash dividend	(37,931)			(37,931)
Issuance of common stock to employees	34,472	$ 1	34,471
Issuance of common stock to employees (in shares)		63,969
Shares withheld for employee taxes	(14,949)		(14,949)
Shares withheld for employee taxes (in shares)		(29,179)
Issuance of common stock to Board of Directors and Scientific Advisory Board	1,704		1,704
Issuance of common stock to Board of Directors and Scientific Advisory Board (in shares)		8,502
Issuance of common stock to employees under an ESPP	1,907		1,907
Issuance of common stock to employees under an ESPP (in shares)		9,156
BALANCE at Dec. 31, 2021	1,099,914	$ 491	658,728	500,212	(18,235)	$ (41,284)	$ 2
BALANCE (in shares) at Dec. 31, 2021		49,065,924				1,365,648	200,000
Net income	210,061			210,061
Other comprehensive income (loss)	(217)				(217)
Cash dividend	(56,996)			(56,996)
Issuance of common stock to employees	27,907		27,907
Issuance of common stock to employees (in shares)		72,769
Shares withheld for employee taxes	$ (9,209)		(9,209)
Shares withheld for employee taxes (in shares)		(31,938)
Common shares repurchased (in shares)	0
Issuance of common stock to Board of Directors and Scientific Advisory Board	$ 1,866		1,866
Issuance of common stock to Board of Directors and Scientific Advisory Board (in shares)		12,218
Issuance of common stock to employees under an ESPP	2,043		2,043
Issuance of common stock to employees under an ESPP (in shares)		17,057
BALANCE at Dec. 31, 2022	1,275,369	$ 491	681,335	653,277	(18,452)	$ (41,284)	$ 2
BALANCE (in shares) at Dec. 31, 2022		49,136,030				1,365,648	200,000
Net income	203,011			203,011
Other comprehensive income (loss)	17,366				17,366
Cash dividend	(66,735)			(66,735)
Issuance of common stock to employees	21,793	$ 1	21,792
Issuance of common stock to employees (in shares)		145,428
Shares withheld for employee taxes	$ (8,206)	$ 0	(8,206)
Shares withheld for employee taxes (in shares)		(58,512)
Common shares repurchased (in shares)	0
Issuance of common stock to Board of Directors and Scientific Advisory Board	$ 2,074		2,074
Issuance of common stock to Board of Directors and Scientific Advisory Board (in shares)		16,808
Issuance of common stock to employees under an ESPP	2,554		2,554
Issuance of common stock to employees under an ESPP (in shares)		17,513
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited		(526,241)
Stock Issued During Period, Value, Restricted Stock Award, Forfeitures	0	$ (5)	5
BALANCE at Dec. 31, 2023	$ 1,447,226	$ 487	$ 699,554	$ 789,553	$ (1,086)	$ (41,284)	$ 2
BALANCE (in shares) at Dec. 31, 2023		48,731,026				1,365,648	200,000

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 203,011	$ 210,061	$ 184,213
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	27,409	24,815	19,968
Amortization of intangibles	15,993	17,459	21,994
Amortization of premium and discount on investments, net	(11,603)	(6,461)	(373)
Impairment of minority investments	0	6,962	0
Stock-based compensation to employees	22,335	28,380	34,871
Stock-based compensation to Board of Directors and Scientific Advisory Board	1,774	1,566	1,404
Deferred income tax (benefit) expense	(3,766)	(26,946)	1,748
Retirement plan expense, net of benefit payments	3,129	5,276	8,875
Decrease (increase) in assets:
Accounts receivable	(47,186)	14,975	(25,378)
Inventory	7,425	(49,060)	(42,569)
Other current assets	(41,574)	(24,843)	(202)
Other assets	4,450	25,971	(32,369)
Increase (decrease) in liabilities:
Accounts payable and accrued expenses	4,047	3,338	1,902
Other current liabilities	(21,481)	20,917	2,105
Deferred revenue	(4,159)	(93,203)	(5,220)
Other liabilities	(5,027)	(32,392)	20,136
Net cash provided by operating activities	154,777	126,815	191,105
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(59,792)	(42,497)	(43,161)
Purchase of intangibles	(66,563)	(4,709)	(394)
Purchases of investments	(531,103)	(701,993)	(642,180)
Proceeds from sale and maturity of investments	574,165	468,456	227,984
Net cash used in investing activities	(83,293)	(280,743)	(457,751)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	2,012	1,570	1,507
Payment of withholding taxes related to stock-based compensation to employees	(8,206)	(9,209)	(14,949)
Cash dividends paid	(66,735)	(56,996)	(37,931)
Net cash used in financing activities	(72,929)	(64,635)	(51,373)
DECREASE IN CASH AND CASH EQUIVALENTS	(1,445)	(218,563)	(318,019)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	93,430	311,993	630,012
CASH AND CASH EQUIVALENTS, END OF YEAR	$ 91,985	$ 93,430	$ 311,993

CONSOLIDATED STATEMENTS OF CASH FLOWS Non-Cash Activities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Significant Noncash Transactions [Line Items]
Unrealized (loss) gain on available-for-sale securities	$ (8,938)	$ (8,100)	$ (295)
Net change in accounts payable and accrued expenses related to purchases of property and equipment	678	3,069	(3,526)
Cash paid for income tax	96,176	72,347	52,650
Common Stock Issued to Board of Directors and Scientific Advisory Board that was Earned and Accrued for in Previous Period [Member]
Other Significant Noncash Transactions [Line Items]
Other significant noncash transaction, value of consideration received	$ 300	$ 300	$ 300

BUSINESS

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS

1.

BUSINESS:

Universal Display Corporation and its subsidiaries (the Company) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. OLEDs are thin, lightweight and power-efficient solid-state devices that emit light and can be manufactured on both flexible and rigid substrates, making them highly suitable for use in full-color displays and as lighting products. OLED displays are capturing a growing share of the display market, especially in the mobile phone, television, monitor, wearable, tablet, notebook and personal computer, augmented reality (AR), virtual reality (VR) and automotive markets. The Company believes this is because OLEDs offer potential advantages over competing display technologies with respect to power efficiency, contrast ratio, viewing angle, video response time, form factor and manufacturing cost. The Company also believes that OLED lighting products have the potential to replace many existing light sources in the future because of their high-power efficiency, excellent color rendering index, low operating temperature and novel form factor. The Company’s technology leadership, intellectual property position, and more than 20 years of experience working closely with leading OLED display manufacturers are some of the competitive advantages that should enable the Company to continue to share in the revenues from OLED displays and lighting products as they gain wider acceptance.

The Company’s primary business strategy is to (1) develop new OLED materials and sell existing and new materials to product manufacturers of products for display applications, such as mobile phones, televisions, monitors, wearables, tablets, portable media devices, notebook computers, personal computers and automotive applications, and specialty and general lighting products; and (2) further develop and either license or otherwise commercialize the Company’s proprietary OLED material, device design and manufacturing technologies to those manufacturers. The Company has established a significant portfolio of proprietary OLED technologies and materials, primarily through internal research and development efforts and acquisitions of patents and patent applications, as well as maintaining long-standing, and establishing new relationships with world-class universities, research institutions and strategic manufacturing partnerships. The Company currently owns, exclusively licenses or has the sole right to sublicense more than 6,000 patents issued and pending worldwide.

The Company manufactures and sells its proprietary OLED materials to customers for evaluation and use in commercial OLED products. The Company also enters into agreements with manufacturers of OLED display and lighting products under which it grants them licenses to practice under the Company’s patents and to use the Company's proprietary know-how. At the same time, the Company works with these and other companies that are evaluating the Company's OLED material, device design and manufacturing technologies for possible use in commercial OLED display and lighting products.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation The Consolidated Financial Statements include the accounts of Universal Display Corporation and its wholly owned subsidiaries, UDC, Inc., UDC Ireland Limited (UDC Ireland), Universal Display Corporation Hong Kong, Limited, Universal Display Corporation Korea, Y.H. (UDC Korea), Universal Display Corporation Japan GK, Universal Display Corporation China, Ltd., Adesis, Inc. (Adesis), UDC Ventures LLC, OVJP Corporation (OVJP Corp) and OLED Material Manufacturing Limited (OMM). All intercompany transactions and accounts have been eliminated. Reclassification of Prior Year Presentation Certain prior year adjustments to reconcile net income to net cash provided by operating activities have been reclassified on the Consolidated Statements of Cash Flows to conform to the current year presentation. These adjustments have been consolidated into their respective operating assets and liabilities accounts, specifically, inventory, other current assets, other assets and deferred revenue. Management’s Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates made are principally in the areas of revenue recognition including estimates of material unit sales and royalties, the useful life of acquired intangibles, lease liabilities, right-of-use assets, the use and recoverability of inventories, intangibles, investments and income taxes including realization of deferred tax assets, stock-based compensation and retirement benefit plan liabilities. Actual results could differ from those estimates. Cash, Cash Equivalents and Investments The Company considers all highly liquid debt instruments purchased with an original maturity (maturity at the purchase date) of three months or less to be cash equivalents. The Company classifies its remaining investments as available-for-sale. These securities (excluding minority equity investments) are carried at fair market value, with unrealized gains and losses reported in shareholders’ equity. Gains or losses on securities sold are based on the specific identification method. Trade Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is a result of chemical sales, royalties and license fees. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant collection risk. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for credit losses would be required. As of December 31, 2023 and 2022, the allowance for credit losses was $166,000 and $279,000, respectively. Inventories Inventories consist of raw materials, work-in-process and finished goods, and are stated at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory valuation and firm committed purchase order assessments are performed on a quarterly basis and those items that are identified to be obsolete or in excess of forecasted usage are written down to their estimated realizable value. Estimates of realizable value are based upon management’s analyses and assumptions, including, but not limited to, forecasted sales levels by product, expected product lifecycle, product development plans and future demand requirements. A 12-month rolling forecast based on factors, including, but not limited to, production cycles, anticipated product orders, marketing forecasts, backlog, and shipment activities is used in the inventory analysis. If market conditions are less favorable than forecasts or actual demand from customers is lower than estimates, additional inventory write-downs may be required. If demand is higher than expected, inventories that had previously been written down may be sold. Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful life of 30 years for buildings, 15 years for building improvements, and three to seven years for office and lab equipment and furniture and fixtures. Repair and maintenance costs are charged to expense as incurred. Additions and betterments are capitalized. Major renewals and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to current operations as incurred. Upon retirement or disposal of assets, the cost and related accumulated depreciation are removed from the Consolidated Balance Sheets and any gain or loss is reflected in other operating expenses. Certain costs of computer software obtained for internal use are capitalized and amortized on a straight-line basis over three years. Costs for maintenance and training, as well as the cost of software that does not add functionality to an existing system, are expensed as incurred. Impairment of Long-Lived Assets Company management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2023, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the years ended December 31, 2022 or 2021. Goodwill and Purchased Intangible Assets Goodwill is tested for impairment in the fourth fiscal quarter and, when specific circumstances dictate, between annual tests. If after assessing the totality of events or circumstances as those described in the qualitative assessment, it is determined that it is more likely than not the fair value of a reporting unit is less than its carrying amount, then a quantitative goodwill impairment test will be performed. Under the quantitative test, the fair value of the reporting unit is compared to its carrying amount including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit would be considered not impaired. However, if the carrying amount of the reporting unit exceeds its fair value, an impairment loss would be recognized in the amount equal to the excess, limited to the total amount of goodwill allocated to that reporting unit. The Company performed its annual impairment assessment as of December 31, 2023 utilizing a qualitative assessment and concluded that it was more likely than not that the fair value of Adesis is greater than its carrying value. Future impairment tests will continue to be performed annually in the fiscal fourth quarter, or sooner if a triggering event occurs. As of December 31, 2023, no indications of impairment existed. Purchased intangible assets with finite lives are carried at cost, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets. Fair Value of Financial Instruments The carrying values of accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value in the accompanying Consolidated Financial Statements due to the short-term nature of those instruments. The Company’s other financial instruments, which include cash equivalents and investments (excluding minority equity investments) are carried at fair value. Fair Value Measurements Fair value is defined as an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. The Company uses valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability and are based on market data obtained from sources independent of the Company. Unobservable inputs reflect assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. Minority Equity Investments The Company accounts for minority equity investments in companies that are not accounted for under the equity method as equity securities without readily determinable fair values. The value of these securities is based on original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment in the same issuer. Under this method, the share of income or loss of such companies is not included in the Consolidated Statements of Income. The carrying value of these investments is included in investments on the Consolidated Balance Sheets. The Company’s policy is to recognize an impairment in the value of its minority equity investments when evidence of an impairment exists. Factors considered in the assessment include a significant adverse change in the regulatory, economic, or technological environment, the completion of new equity financing that may indicate a decrease in value, the failure to complete new equity financing arrangements after seeking to raise additional funds, or the commencement of proceedings under which the assets of the business may be placed in receivership or liquidated to satisfy the claims of debt and equity stakeholders. The impairment in the value of minority equity investments is included in the other (loss) income, net line item on the Consolidated Statements of Income. Leases The Company is a lessee in operating leases primarily incurred to facilitate manufacturing, research and development, and selling, general and administrative activities. At contract inception, the Company determines if an arrangement is or contains a lease, and if so recognizes a right-of-use asset and lease liability at the lease commencement date. For operating leases, the lease liability is measured at the present value of the unpaid lease payments at the lease commencement date, whereas for finance leases, the lease liability is initially measured at the present value of the unpaid lease payments and subsequently measured at amortized cost using the interest method. Operating lease right-of-use assets are included in other assets on the Consolidated Balance Sheets. The short-term portion of operating lease liabilities is included in other current liabilities on the Consolidated Balance Sheets and the long-term portion is included in other liabilities on the Consolidated Balance Sheets. As of December 31, 2023, the Company had no leases that qualified as financing arrangements. Key estimates and judgments include how the Company determines the discount rate used to discount the unpaid lease payments to present value and the lease term. The Company monitors for events or changes in circumstances that could potentially require recognizing an impairment loss. Revenue Recognition and Deferred Revenue Material sales relate to the Company’s sale of its OLED materials for incorporation into its customers’ commercial OLED products or for their OLED development and evaluation activities. Revenue associated with material sales is generally recognized at the time title passes, which is typically at the time of shipment or at the time of delivery, depending upon the contractual agreement between the parties. Revenue may be recognized after control of the material passes in the event the transaction price includes variable consideration. For example, a customer may be provided an extended opportunity to stock materials prior to use in mass production and given a general right of return not conditioned on breaches of warranties associated with the specific product. In such circumstances, revenue will be recognized at the earlier of the expiration of the customer’s general right of return or once it becomes unlikely that the customer will exercise its right of return. The vast majority of revenue attributed to material sales is determined through technology license agreements and material supply agreements the terms of which are jointly agreed upon with the Company’s customers. The remaining revenue recognized is in the form of contract research services revenue earned by the Company’s subsidiary, Adesis, Inc., and the Company’s occasional material sales to smaller customers. None of the revenue recognized during the years ended December 31, 2023, 2022 or 2021 resulted solely from royalty or license fee arrangements as to which there were not associated material sales. The rights and benefits to the Company’s OLED technologies are conveyed to the customer through technology license agreements and material supply agreements. The Company believes that the licenses and materials sold under these combined agreements are not distinct from each other for financial reporting purposes and as such, they are accounted for as a single performance obligation. Accordingly, total contract consideration is estimated and recognized over the contract term based on material units sold at the estimated per unit fee over the life of the contract. Total contract consideration is allocated to material sales and royalty and licensing fees on the Consolidated Statements of Income based on contract pricing. Various estimates are relied upon to recognize revenue. The Company estimates total material units to be purchased by its customers over the contract term based on historical trends, industry estimates and its forecast process. Management uses the expected value method to estimate the material per unit fee. Additionally, management estimates the sales-based portion of royalty revenue based on the estimated net sales revenue of its customers over the contract term. Contract research services revenue is revenue earned by Adesis by providing chemical materials synthesis research, development and commercialization for non-OLED applications on a contractual basis. These services range from intermediates for structure-activity relationship studies, reference agents and building blocks for combinatorial synthesis, re-synthesis of key intermediates, specialty organic chemistry needs, and selective toll manufacturing. These services are provided to third-party pharmaceutical and life sciences firms and other technology firms at fixed costs or predetermined rates on a contract basis. Revenue is recognized as services are performed with billing schedules and payment terms negotiated on a contract-by-contract basis. Payments received in excess of revenue recognized are recorded as deferred revenue. In other cases, services may be provided and revenue is recognized before the customer is invoiced. In these cases, revenue recognized will exceed amounts billed and the difference, representing amounts which are currently unbillable to the customer pursuant to contractual terms, is recorded as an unbilled receivable. Technology development and support revenue is revenue earned from development and technology evaluation agreements and commercialization assistance fees. Technology development and support revenue is included in contract research services on the Consolidated Statements of Income. On December 2, 2022, the Company entered into a commercial patent license agreement with Samsung Display Co., Ltd. (SDC), replacing a previous license agreement that had been in place since 2018. This agreement, which covers the manufacture and sale of specified OLED display materials, was effective as of January 1, 2023 and lasts through the end of 2027 with an additional two-year extension option for SDC. Under this agreement, the Company is being paid a license fee, which includes quarterly and annual payments over the agreement term of five years. The agreement conveys to SDC the non-exclusive right to use certain of the Company's intellectual property assets for a limited period of time that is less than the estimated life of the assets. At the same time the Company entered into the current commercial license agreement with SDC, the Company also entered into a new supplemental material purchase agreement with SDC, which lasts for the same term as the license agreement and is subject to the same extension option. This new material purchase agreement replaced a previous purchase agreement that had been in place since 2018. Under the supplemental material purchase agreement, SDC agrees to purchase red and green phosphorescent emitter materials from the Company for use in the manufacture of licensed products. This amount purchased is subject to SDC’s requirements for phosphorescent emitter materials and the Company’s ability to meet these requirements over the term of the supplemental agreement. In 2015, the Company entered into an OLED patent license agreement and an OLED commercial supply agreement with LG Display Co., Ltd. (LG Display), which were effective as of January 1, 2015. The terms of these agreements were extended by a January 1, 2021 amendment through the end of 2025. The patent license agreement provides LG Display a non-exclusive, royalty bearing portfolio license to make and sell OLED displays under the Company's patent portfolio. The patent license calls for license fees, prepaid royalties and running royalties on licensed products. The OLED commercial supply agreement provides for the sale of materials for use by LG Display, which may include phosphorescent emitters and host materials. The agreements provide for certain other minimum obligations relating to the volume of material sales anticipated over the lives of the agreements as well as minimum royalty revenue. In 2023, the Company entered into new long-term, multi-year agreements with BOE Technology Group Co., Ltd. (BOE). Under these agreements, the Company has granted BOE non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The Company supplies phosphorescent OLED materials to BOE for use in its licensed products. In 2019, the Company entered into an evaluation and commercial supply relationship with Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. (CSOT). In 2020, the Company entered into long-term, multi-year agreements with CSOT. Under these agreements, the Company has granted CSOT non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The Company also supplies phosphorescent OLED materials to CSOT for use in its licensed products. In 2018, the Company entered into long-term, multi-year OLED patent license and material purchase agreements with Visionox Technology, Inc. (Visionox). Under the license agreement, the Company granted certain of Visionox’s affiliates non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The license agreement calls for license fees and running royalties on licensed products. Additionally, the Company supplies phosphorescent OLED materials to Visionox for use in its licensed products. In 2021, the Company announced that it had extended the Visionox agreement by entering into new five-year OLED material supply and license agreements with a new affiliate of Visionox, Visionox Hefei Technology Co. Ltd. In 2016, the Company entered into long-term, multi-year OLED patent license and material purchase agreements with Tianma Micro-electronics Co., Ltd. (Tianma). Under the license agreement, the Company has granted Tianma non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The license agreement calls for license fees and running royalties on licensed products. Additionally, the Company supplies phosphorescent OLED materials to Tianma for use in its licensed products. In 2021, the parties extended the terms of both the patent license and material purchase agreements for an additional multi-year-term. All material sales transactions that are not variable consideration transactions are billed and due within 90 days and substantially all are transacted in U.S. dollars. Cost of Sales Cost of sales consists of labor and material costs associated with the production of materials processed at the facilities of the Company's manufacturing partner, PPG Industries, Inc. (PPG) and at the Company's internal facilities. The Company’s portion of cost of sales also includes depreciation of manufacturing equipment, as well as manufacturing overhead costs and inventory adjustments for excess and obsolete inventory. Research and Development Expenditures for research and development are charged to expense as incurred. Patent Costs Costs associated with patent applications, patent prosecution, patent defense and the maintenance of patents are charged to expense as incurred. Costs to successfully defend a challenge to a patent are capitalized to the extent of an evident increase in the value of the patent. Costs that relate to an unsuccessful outcome are charged to expense. Amortization of Acquired Technology Amortization costs primarily relate to technology acquired from Merck KGaA, Darmstadt, Germany (Merck KGaA), BASF SE (BASF) and Fujifilm Corporation (Fujifilm). The Merck KGaA acquisition was completed on April 28, 2023. The BASF and Fujifilm acquisitions were completed in the years ended December 31, 2016 and 2012, respectively. Acquisition costs are being amortized over a period of 10 years for the Merck KGaA and BASF patents. The Fujifilm acquired technology was fully amortized over a period of 10 years that ended in July 2022. Amortization of Other Intangible Assets Other intangible assets from the Adesis acquisition are being amortized over a period of 10 to 15 years. See Note 7 for further discussion. Translation of Foreign Currency Financial Statements and Foreign Currency Transactions The Company’s reporting currency is the U.S. dollar. The functional currency for the UDC Ireland and UDC Korea subsidiaries are also the U.S. dollar and the functional currency for the OMM subsidiary and each of the Company's other Asia-Pacific foreign subsidiaries is its respective local currency. The Company translates the amounts included in the Consolidated Statements of Income from OMM and its Asia-Pacific foreign subsidiaries into U.S. dollars at weighted-average exchange rates, which the Company believes are representative of the actual exchange rates on the dates of the transactions. The Company's OMM subsidiary and each of the Company's other Asia-Pacific foreign subsidiaries' assets and liabilities are translated into U.S. dollars from the local currency at the actual exchange rates as of the end of each reporting date, and the Company records the resulting foreign exchange translation adjustments in the Consolidated Balance Sheets as a component of accumulated other comprehensive loss. The overall effect of the translation of foreign currency and foreign currency transactions to date has been insignificant. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount of which the likelihood of realization is greater than 50%. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties, if any, related to unrecognized tax benefits as a component of tax expense. Share-Based Payment Awards The Company recognizes in the Consolidated Statements of Income the grant-date fair value of equity-based awards such as shares issued under employee stock purchase plans, restricted stock awards, restricted stock units and performance unit awards issued to employees and directors. The grant-date fair value of stock awards is based on the closing price of the stock on the date of grant. The fair value of share-based awards is recognized as compensation expense on a straight-line basis over the requisite service period, net of forfeitures. The Company issues new shares upon the respective grant, exercise or vesting of the share-based payment awards, as applicable. Performance unit awards are subject to either a performance-based or market-based vesting requirement. For performance-based vesting, the grant-date fair value of the award, based on fair value of the Company's common stock, is recognized over the service period based on an assessment of the likelihood that the applicable performance goals will be achieved, and compensation expense is periodically adjusted based on actual and expected performance. Compensation expense for performance unit awards with market-based vesting is calculated based on the estimated fair value as of the grant date utilizing a Monte Carlo simulation model and is recognized over the service period on a straight-line basis. Recent Accounting Pronouncements Adoption of New Accounting Standards In October 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with FASB ASC 606. The adoption of ASU 2021-08, beginning on January 1, 2023, did not have a impact on the Consolidated Financial Statements and related disclosures. In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, Liabilities—Supplier Finance Programs (Subtopic 450-50): Disclosure of Supplier Finance Program Obligations, which require disclosures about a buyer's supplier finance program. The adoption of ASU 2022-04, beginning on January 1, 2023, did not have a impact on the Consolidated Financial Statements and related disclosures. Accounting Standards Issued But Not Yet Adopted In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Under this standard, a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective January 1, 2024, and will not have a significant impact on the Consolidated Financial Statements and related disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The standard improves the reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 becomes effective January 1, 2024, and the Company is evaluating the potential impact of this standard on the Consolidated Financial Statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The standard enhances to the annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity's worldwide operations. ASU 2023-09 becomes effective January 1, 2025, and the Company is evaluating the potential impact of this standard on its income tax disclosures.

CASH, CASH EQUIVALENTS AND INVESTMENTS

12 Months Ended

Dec. 31, 2023

Cash and Cash Equivalents [Abstract]

CASH, CASH EQUIVALENTS AND INVESTMENTS

3.

CASH, CASH EQUIVALENTS AND INVESTMENTS:

The Company’s portfolio of marketable fixed income securities consists of U.S. Government bonds and corporate bonds. The Company considers all highly liquid debt instruments purchased with an original maturity (maturity at the purchase date) of three months or less to be cash equivalents. The Company classifies its remaining debt security investments as available-for-sale. These debt securities are carried at fair market value, with unrealized gains and losses reported in shareholders’ equity. Gains or losses on securities sold are based on the specific identification method.

Cash and Cash Equivalents

The following table provides details regarding the Company’s portfolio of cash and cash equivalents (in thousands):


	Amortized		Unrealized				Aggregate Fair
Cash and Cash Equivalents Classification	Cost		Gains		(Losses)		Market Value
December 31, 2023
Cash accounts in banking institutions	$	91,717	$	—	$	—	$	91,717
Money market accounts		268		—		—		268
	$	91,985	$	—	$	—	$	91,985
December 31, 2022
Cash accounts in banking institutions	$	86,268	$	—	$	—	$	86,268
Money market accounts		7,162		—		—		7,162
	$	93,430	$	—	$	—	$	93,430

Short-term Investments

The following table provides details regarding the Company’s portfolio of short-term investments (in thousands):


	Amortized		Unrealized					Aggregate Fair
Short-term Investments Classification	Cost		Gains		(Losses)			Market Value
December 31, 2023
Corporate bonds	$	1,763	$	1	$	(5	)	$	1,759
U.S. Government bonds		420,769		303		(694	)		420,378
	$	422,532	$	304	$	(699	)	$	422,137
December 31, 2022
Corporate bonds	$	150,698	$	—	$	(910	)	$	149,788
U.S. Government bonds		339,472		32		(4,947	)		334,557
	$	490,170	$	32	$	(5,857	)	$	484,345

Long-term Corporate Bond and U.S. Government Bond Investments

The following table provides details regarding the Company’s portfolio of long-term investments (in thousands):


	Amortized		Unrealized					Aggregate Fair
Long-term Investments Classification	Cost		Gains		(Losses)			Market Value
December 31, 2023
U.S. Government bonds	$	284,053	$	1,457	$	(8	)	$	285,502
	$	284,053	$	1,457	$	(8	)	$	285,502
December 31, 2022
Corporate bonds	$	2,479	$	—	$	(28	)	$	2,451
U.S. Government bonds		247,464		52		(2,152	)	$	245,364
	$	249,943	$	52	$	(2,180	)	$	247,815

Minority Equity Investments

The Company’s portfolio of minority equity investments consists of investments in privately held early-stage companies primarily motivated for the Company to gain early access to new technology and are passive in nature in that the Company typically does not seek to obtain representation on the boards of directors of the companies in which it invests. Minority equity investments are included in investments on the Consolidated Balance Sheets. As of December 31, 2023, the Company had minority equity investments in five entities with a total carrying value of $14.0 million accounted for as equity securities without readily determinable fair values as compared to four minority equity investments with a total carrying value of $12.0 million as of December 31, 2022.

During the year ended December 31, 2022, the Company recognized an impairment in the value of two of its minority equity investments, an impairment of an equity security investment in the amount of $3.0 million and an impairment of a long-term convertible note investment of $4.0 million which had been acquired during the year ended December 31, 2022. During the year ended December 31, 2023, the Company did not recognize an impairment in the value of its minority equity investments. The impairment in the value of minority equity investments are included in the other (loss) income, net line item on the Consolidated Statements of Income.

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

4.

FAIR VALUE MEASUREMENTS:

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2023 (in thousands):


			Fair Value Measurements, Using
	Total Carrying Value as of December 31, 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	268	$	268	$	—	$	—
Short-term Corporate bonds		1,759		1,759		—		—
Short-term U.S. Government bonds		420,378		420,378		—		—
Long-term U.S. Government bonds		285,502		285,502		—		—

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 (in thousands):


			Fair Value Measurements, Using
	Total Carrying Value as of December 31, 2022		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	7,162	$	7,162	$	—	$	—
Short-term Corporate bonds		149,788		149,788		—		—
Short-term U.S. Government bonds		334,557		334,557		—		—
Long-term Corporate bonds		2,451		2,451		—		—
Long-term U.S. Government bonds		245,364		245,364		—		—

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management’s own assumptions used to measure assets and liabilities at fair value. A financial asset’s or liability’s classification is determined based on the lowest level input that is significant to the fair value measurement.

Changes in fair value of the debt investments are recorded as unrealized gains and losses in accumulated other comprehensive loss on the Consolidated Balance Sheets and any credit losses on debt investments are recorded as an allowance for credit losses with an offset recognized in other (loss) income, net on the Consolidated Statements of Income. There were no credit losses on debt investments as of December 31, 2023 or December 31, 2022.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INVENTORY

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

INVENTORY

5.

INVENTORY:

Inventory consisted of the following (in thousands):


	December 31,
	2023		2022
Raw materials	$	113,400	$	115,448
Work-in-process		9,433		7,626
Finished goods		52,962		60,146
Inventory	$	175,795	$	183,220

The Company recorded an inventory reserve of $8.5 million, $3.6 million and $3.6 million for the years ended December 31, 2023, 2022 and 2021, respectively, due to excess inventory levels in certain products.

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

6.

PROPERTY AND EQUIPMENT:

Property and equipment, net consist of the following (in thousands):


	December 31,
	2023			2022
Land	$	12,230		$	2,642
Building and improvements		116,903			99,586
Office and lab equipment		148,465			129,697
Furniture, fixtures and computer related assets		18,970			18,071
Construction-in-progress		22,490			10,567
		319,058			260,563
Less: Accumulated depreciation		(143,908	)		(117,118	)
Property and equipment, net	$	175,150		$	143,445

Depreciation expense was $27.4 million, $24.8 million and $20.0 million for the years ended December 31, 2023, 2022 and 2021, respectively. The increase in property and equipment, net for the year ended December 31, 2023 is primarily due to the purchases of two previously leased facilities for an aggregate cost of $23.4 million and ongoing renovation activities at our research and development center in Ewing, New Jersey.

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2023

Finite-Lived Intangible Assets, Net [Abstract]

GOODWILL AND INTANGIBLE ASSETS

7.

GOODWILL AND INTANGIBLE ASSETS:

The Company monitors the recoverability of goodwill annually or whenever events or changes in circumstances indicate the carrying value may not be recoverable. Purchased intangible assets subject to amortization consist of acquired technology and other intangible assets that include trade names, customer relationships and developed intellectual property (IP) processes.

Acquired Technology

Acquired technology primarily consists of acquired license rights for patents and know-how obtained from Merck KGaA, BASF and Fujifilm. These intangible assets consist of the following (in thousands):


	December 31,
	2023 (1)			2022
PD-LD, Inc.	$	—		$	1,481
Motorola		—			15,909
Merck KGaA		66,012			—
BASF		95,989			95,989
Fujifilm		109,462			109,462
Other		5,712			5,212
		277,175			228,053
Less: Accumulated amortization		(186,850	)		(189,671	)
Acquired technology, net	$	90,325		$	38,382

(1)

During the year ended December 31, 2023, the gross value and accumulated amortization associated with the PD-LD, Inc. and Motorola patent portfolios have been removed from the table as the underlying patents have reached the end of their useful lives.

Amortization expense related to acquired technology was $14.6 million, $16.0 million and $20.6 million for the years ended December 31, 2023, 2022 and 2021, respectively. Amortization expense is included in amortization of acquired technology and other intangible assets expense line item on the Consolidated Statements of Income and is expected to be $16.8 million in each of the years ending December 31, 2024 and 2025, $12.0 million in the year ending December 31, 2026, $7.2 million in each of the years ending December 2027 and 2028, and $30.3 million in total thereafter.

Merck KGaA Patent Acquisition

In April 2023, UDC Ireland entered into a Patent Sale and License Agreement with Merck KGaA. Under this agreement, Merck KGaA sold to UDC Ireland all of its rights, title and interest to over 550 of its owned and licensed OLED-related patents and patent applications in exchange for a cash payment of $66.0 million. The Patent Sale and License Agreement contains customary representations, warranties and covenants of the parties. UDC Ireland recorded the payment of $66.0 million as acquired technology, which is being amortized over a period of 10 years.

BASF Patent Acquisition

On June 28, 2016, UDC Ireland entered into and consummated an IP Transfer Agreement with BASF. Under the IP Transfer Agreement, BASF sold to UDC Ireland all of its rights, title and interest to certain of its owned and co-owned intellectual property rights relating to the composition, development, manufacture and use of OLED materials, including OLED lighting and display stack technology, as well as certain tangible assets. The intellectual property includes knowhow and more than 500 issued and pending patents in the area of phosphorescent materials and technologies. These assets were acquired in exchange for a cash payment of €86.8 million ($95.8 million). In addition, UDC Ireland also took on certain rights and obligations under three joint research and development agreements to which BASF was a party. The IP Transfer Agreement also contains customary representations, warranties and covenants of the parties. UDC Ireland recorded the payment of €86.8 million ($95.8 million) and acquisition costs incurred of $217,000 as acquired technology, which is being amortized over a period of 10 years.

Fujifilm Patent Acquisition

On July 23, 2012, the Company entered into a Patent Sale Agreement with Fujifilm. Under the agreement, Fujifilm sold more than 1,200 OLED-related patents and patent applications in exchange for a cash payment of $105.0 million, plus $4.5 million in costs incurred in connection with the purchase. The agreement contains customary representations and warranties and covenants, including respective covenants not to sue by both parties thereto. The agreement permitted the Company to assign all of its rights and obligations under the agreement to its affiliates, and the Company assigned, prior to the consummation of the transactions contemplated by the agreement, its rights and obligations to UDC Ireland. The transactions contemplated by the agreement were consummated on July 26, 2012. The Company recorded the $105.0 million plus $4.5 million of purchase costs as acquired technology, which was amortized over a period of 10 years that ended in July 2022.

Other Intangible Assets

As a result of the Adesis acquisition in June 2016, the Company recorded $16.8 million of other intangible assets, including $10.5 million assigned to customer relationships with a weighted average life of 11.5 years, $4.8 million to internally developed IP, processes and recipes with a weighted average life of 15 years, and $1.5 million to trade name and trademarks with a weighted average life of 10 years.

At December 31, 2023, these other intangible assets consist of the following (in thousands):


	December 31, 2023
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Customer relationships	$	10,520	$	(6,801	)	$	3,719
Developed IP, processes and recipes		4,820		(2,388	)		2,432
Trade name/Trademarks		1,500		(1,118	)		382
Other		448		(107	)		341
Total identifiable other intangible assets	$	17,288	$	(10,414	)	$	6,874

Amortization expense related to other intangible assets was $1.4 million for each of the years ended December 31, 2023, 2022, and 2021. Amortization expense is included in amortization of acquired technology and other intangible assets expense line item on the Consolidated Statements of Income and is expected to be $1.4 million for each of the next three fiscal years (2024 - 2026), $1.3 million for the year ending December 31, 2027, $422,000 for the year ending December 31, 2028, and $1.0 million in total thereafter.

Goodwill

As a result of the Adesis acquisition, the Company recorded $15.5 million of goodwill. The Company performs its annual assessment of goodwill during the fourth quarter of the fiscal year unless events suggest an impairment may have been incurred in an interim period using Adesis’ standalone financial operating performance information. Application of the goodwill impairment test requires the exercise of judgment, including the determination of the fair value of each reporting unit, as Adesis is considered to be the reporting unit. As part of the annual assessment of goodwill completed during the fourth quarter ended December 31, 2023, there were no significant indicators to conclude that an impairment of the goodwill associated with the acquisition of Adesis had occurred.

OTHER ASSETS

12 Months Ended

Dec. 31, 2023

Prepaid Expense and Other Assets [Abstract]

Other assets

8.

OTHER ASSETS:

Other assets consist of the following (in thousands):


	December 31,
	2023		2022
Long-term taxes receivable	$	60,146	$	63,915
Right-of-use assets		24,910		31,486
Long-term unbilled receivables		9,074		—
Long-term contract assets		9,278		11,651
Other long-term assets		1,881		2,687
Other assets	$	105,289	$	109,739

See Notes 9 and 20 for further explanation on right-of-use assets and long-term taxes receivable, respectively.

LEASES

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

LEASES

9.

LEASES:

The Company has entered into operating leases to facilitate the expansion of its manufacturing, research and development, and selling, general and administrative activities. For purposes of calculating operating lease liabilities, lease terms may be deemed to include options to extend or terminate the lease when those events are reasonably certain to occur. The interest rate implicit in lease contracts is typically not readily determinable and as such the Company uses the appropriate incremental borrowing rate based on information available at the lease commencement date in determining the present value of the lease payments. Current lease agreements do not contain any residual value guarantees or material restrictive covenants. As of December 31, 2023, the Company did not have any finance leases and no additional operating leases that have not yet commenced.

The following table presents the Company’s operating lease cost and supplemental cash flow information related to the Company’s operating leases (in thousands):


	Year Ended December 31,
	2023		2022		2021
Operating lease cost	$	4,639	$	4,436	$	3,637
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	$	1,072	$	4,750	$	26,174

The following table presents the Company’s operating lease right-of-use assets and liabilities (in thousands):


	December 31,
	2023		2022
Right-of-use assets	$	24,910	$	31,486
Short-term lease liabilities		3,533		3,737
Long-term lease liabilities		22,855		29,039

The following table presents weighted average assumptions used to compute the Company’s right-of-use assets and lease liabilities:


	December 31, 2023
Weighted average remaining lease term (in years)		6.7
Weighted average discount rate		3.7	%

As of December 31, 2023, current operating leases had remaining terms between three and eight years with options to extend the lease terms.

Undiscounted future minimum lease payments as of December 31, 2023, by year and in the aggregate, having non-cancelable lease terms in excess of one year were as follows (in thousands):


	Maturities of
	Operating Lease Liabilities
2024	$	4,267
2025		4,321
2026		4,401
2027		4,323
2028		3,996
Thereafter		8,083
Total lease payments		29,391
Less: imputed interest		(3,003	)
Present value of lease payments	$	26,388

ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

ACCRUED EXPENSES

10.

ACCRUED EXPENSES:

Accrued expenses consist of the following (in thousands):


	December 31,
	2023		2022
Compensation	$	29,456	$	31,751
PPG Industries, Inc. agreement		11,962		9,864
Consulting		2,121		910
Professional fees		1,124		906
Research and development agreements		822		662
Royalties		647		877
Other		5,948		6,032
Accrued expenses	$	52,080	$	51,002

RESEARCH AND LICENSE AGREEMENTS WITH ACADEMIC PARTNERS

12 Months Ended

Dec. 31, 2023

Research and Development [Abstract]

RESEARCH AND LICENSE AGREEMENTS WITH ACADEMIC PARTNERS

11.

RESEARCH AND LICENSE AGREEMENTS WITH ACADEMIC PARTNERS:

The Company has long-standing relationships with a number of academic institutions that undertake funded research projects, including Princeton University (Princeton) and the University of Southern California (USC).

Under the current license agreement among the Company, Princeton and USC, the universities have granted the Company worldwide, exclusive license rights, with rights to sublicense, to make, have made, use, lease and/or sell products and to practice processes based on patent applications and issued patents arising out of research performed by the universities for the Company. The Company recorded royalty expense in connection with this agreement of $575,000, $853,000 and $691,000 for the years ended December 31, 2023, 2022 and 2021, respectively.

The Company also makes payments under the current research agreement with USC on a quarterly basis as actual expenses are incurred. As of December 31, 2023, the Company was obligated to pay USC up to $2.0 million for work to be performed during the remaining extended term. The Company recorded research and development expense in connection with work performed under the agreement of $1.1 million, $905,000 and $1.3 million for the years ended December 31, 2023, 2022 and 2021, respectively.

OTHER LIABILITIES

12 Months Ended

Dec. 31, 2023

Other Liabilities [Abstract]

OTHER LIABILITIES

12.

OTHER LIABILITIES:

Other liabilities consist of the following (in thousands):


	December 31,
	2023		2022
Long-term lease liabilities	$	22,855	$	29,039
Long-term taxes payable		15,749		14,592
Other long-term liabilities		54		54
Other liabilities	$	38,658	$	43,685

See Notes 9 and 20 for further explanation on long-term lease liabilities and long-term taxes payable, respectively.

EQUITY AND CASH COMPENSATION UNDER THE PPG AGREEMENTS

12 Months Ended

Dec. 31, 2023

Long-Term Commitment (Excluding Unconditional Purchase Obligation) [Abstract]

EQUITY AND CASH COMPENSATION UNDER THE PPG AGREEMENTS

13.

EQUITY AND CASH COMPENSATION UNDER THE PPG AGREEMENTS:

On September 22, 2011, the Company entered into an Amended and Restated OLED Materials Supply and Service Agreement with PPG (the New OLED Materials Agreement), which, effective as of October 1, 2011, replaced the original OLED Materials Agreement with PPG. The term of the New OLED Materials Agreement, by amendment in February 2021, runs through December 31, 2024, and thereafter is automatically renewed for additional one-year terms, unless terminated by the Company by providing prior notice of one year or terminated by PPG by providing prior notice of two years. The New OLED Materials Agreement contains provisions that are substantially similar to those of the original OLED Materials Agreement. Under the New OLED Materials Agreement, PPG continues to assist the Company in developing its proprietary OLED materials and supplying the Company with those materials for evaluation purposes and for resale to its customers.

Under the New OLED Materials Agreement, the Company compensates PPG on a cost-plus basis for the services provided during each calendar quarter. The Company is required to pay for some of these services in all cash. Up to 50% of the remaining services are payable, at the Company’s sole discretion, in cash or shares of the Company’s common stock, with the balance payable in cash. The actual number of shares of common stock issuable to PPG is determined based on the average closing price for the Company’s common stock during a specified number of days prior to the end of each calendar half-year period ending on March 31 and September 30. If, however, this average closing price is less than $20.00, the Company is required to compensate PPG in cash. No shares have been issued for services rendered by PPG since the inception of the contract.

The Company is also required to reimburse PPG for raw materials used for research and development. The Company records the purchases of these raw materials as a current asset until such materials are used for research and development efforts.

In February 2021, the Company entered into an amendment to the New OLED Materials Agreement extending the term of the agreement and specifying operation and maintenance services to be provided by PPG affiliate, PPG SCM Ireland Limited (PPG SCM), to UDC Ireland, at the Company’s manufacturing site in Shannon, Ireland that UDC Ireland’s wholly-owned subsidiary, OLED Material Manufacturing Limited (OMM), began leasing at such time for the production of OLED materials. OMM purchased the site in September 2023 and the Company amended and restated the February 2021 amendment to reflect OMM’s ownership and PPG SCM’s updated operation and maintenance services after such purchase. Facility improvements have been completed and operations commenced in June 2022. As with the initial New OLED Materials Agreement, the Company compensates PPG on a cost-plus basis for the services provided at the Shannon manufacturing facility.

The Company recorded research and development expense of $9.1 million, $7.3 million and $3.6 million for the years ended December 31, 2023, 2022 and 2021, respectively, in relation to the cash portion of the reimbursement of expenses and work performed by PPG, excluding amounts paid for commercial chemicals.

SHAREHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

SHAREHOLDERS' EQUITY

14.

SHAREHOLDERS' EQUITY:

Preferred Stock

The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 5,000,000 shares of $0.01 par value preferred stock with designations, rights and preferences determined from time-to-time by the Company’s Board of Directors. Accordingly, the Company’s Board of Directors is empowered, without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of shareholders of the Company’s common stock.

In 1995, the Company issued 200,000 shares of Series A Nonconvertible Preferred Stock (Series A) to American Biomimetics Corporation (ABC) pursuant to a certain Technology Transfer Agreement between the Company and ABC. The Series A shares have a liquidation value of $7.50 per share. Series A shareholders, as a single class, have the right to elect two members of the Company’s Board of Directors. This right has never been exercised. Holders of the Series A shares are entitled to one vote per share on matters which shareholders are generally entitled to vote. The Series A shareholders are not entitled to any dividends.

As of December 31, 2023, the Company had issued 200,000 shares of preferred stock, all of which were outstanding.

Common Stock

The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 200,000,000 shares of $0.01 par value common stock. Each share of the Company’s common stock entitles the holder to one vote on all matters to be voted upon by the shareholders.

As of December 31, 2023, the Company had issued 48,731,026 shares of common stock, of which 47,365,378 were outstanding. During the years ended December 31, 2023 and 2022, the Company repurchased no shares of common stock.

Dividends

During the year ended December 31, 2023, the Company declared and paid cash dividends of $1.40 per common share, or $66.7 million, on the Company’s outstanding common stock.

On February 20, 2024, the Company’s Board of Directors declared a first quarter dividend of $0.40 per share to be paid on March 29, 2024 to all shareholders of record of the Company's common stock as of the close of business on March 15, 2024. All future dividends will be subject to the approval of the Company’s Board of Directors.

ACCUMULATED OTHER COMPREHENSIVE LOSS

12 Months Ended

Dec. 31, 2023

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

15.

ACCUMULATED OTHER COMPREHENSIVE LOSS:

Amounts related to the changes in accumulated other comprehensive loss were as follows (in thousands):


	Unrealized Gain (Loss) on Available-for- Sale-Securities			Net Unrealized Gain (Loss) on Retirement Plan (2)			Change in Cumulative Foreign Currency Translation Adjustment			Total			Affected Line items in the Consolidated Statements of Income
Balance January 1, 2021, net of tax	$	91		$	(36,075	)	$	(35	)	$	(36,019	)
Other comprehensive (loss) gain before reclassification		(233	)		13,620			(39	)		13,348
Plan amendment cost		—			(283	)		—			(283	)
Reclassification to net income (1)		—			4,719			—			4,719		Selling, general and administrative, research and development and cost of sales
Change during period		(233	)		18,056			(39	)		17,784
Balance December 31, 2021, net of tax		(142	)		(18,019	)		(74	)		(18,235	)
Other comprehensive (loss) gain before reclassification		(7,745	)		5,971			(480	)		(2,254	)
Reclassification to net income (1)		—			2,037			—			2,037		Selling, general and administrative, research and development and cost of sales
Change during period		(7,745	)		8,008			(480	)		(217	)
Balance December 31, 2022, net of tax		(7,887	)		(10,011	)		(554	)		(18,452	)
Other comprehensive (loss) gain before reclassification		8,745			7,207			418			16,370
Reclassification to net income (1)		—			996			—			996		Selling, general and administrative, research and development and cost of sales
Change during period		8,745			8,203			418			17,366
Balance December 31, 2023, net of tax	$	858		$	(1,808	)	$	(136	)	$	(1,086	)

(1)

The Company reclassified amortization of prior service cost, actuarial loss and plan amendment cost for its retirement plan from accumulated other comprehensive loss to net income of $1.0 million, $2.0 million and $4.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Refer to Note 17: Employee Retirement Plans

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

16.

STOCK-BASED COMPENSATION:

Equity Compensation Plan

On June 15, 2023, the shareholders of the Company voted to approve the Universal Display Corporation 2023 Equity Compensation Plan (the “Equity Compensation Plan”), which replaced the Universal Display Corporation 2014 Equity Compensation Plan. The Equity Compensation Plan provides for the granting of incentive and nonqualified stock options, shares of common stock, stock appreciation rights and performance units to employees, directors and consultants of the Company. Stock options are exercisable over periods determined by the Company’s Human Capital Committee, but for no longer than 10 years from the grant date. The total number of shares that may be subject to awards under the Equity Compensation Plan is equal to the shares that were available for issuance and not subject to an award under the 2014 Equity Compensation Plan at the time it was replaced by the Equity Compensation Plan, subject to adjustment with respect to shares underlying any outstanding award granted under the Equity Compensation Plan or the 2014 Equity Compensation Plan that may expire, or be terminated, surrendered or forfeited for any reason, without issuance of such

shares. As of December 31, 2023, there were 1,519,235 shares that remained available to be granted under the Equity Compensation Plan. The Equity Compensation Plan will terminate on June 15, 2033.

Restricted Stock Award and Units

The Company has issued restricted stock awards and units to employees and non-employees with vesting terms of one to five years. The fair value is equal to the market price of the Company’s common stock on the date of grant for awards granted to employees. Consistent with the accounting for equity-classified awards issued to employees, our equity-classified nonemployee share-based awards are measured at the grant date fair value. Expense for restricted stock awards and units is amortized ratably over the vesting period for the awards issued to employees and using a graded vesting method for the awards issued to non-employees.

The following table summarizes the activity related to restricted stock unit (RSU) share based payment awards:


	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested, January 1, 2023		230,223		$	165.13
Granted		121,896			136.22
Vested		(132,010	)		163.85
Forfeited		(3,623	)		152.21
Unvested, December 31, 2023		216,486		$	149.68

The weighted average grant-date fair value per unit of RSU awards granted was $136.22, $140.37 and $208.67 during the years ended December 31, 2023, 2022 and 2021, respectively. The grant date fair value of RSUs that vested during the year was $21.6 million for the year ended December 31, 2023, $18.0 million for the year ended December 31, 2022 and $12.5 million for the year ended December 31, 2021. The fair value of RSUs as of their respective vesting dates was $18.6 million for the year ended December 31, 2023, $15.3 million for the year ended December 31, 2022 and $15.1 million for the year ended December 31, 2021.

The following table summarizes the activity related to restricted stock award (RSA) share based payment awards:


	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested, January 1, 2023		33,637		$	178.37
Granted		2,366			126.87
Vested		(18,456	)		178.82
Unvested, December 31, 2023		17,547		$	170.96

The weighted average grant-date fair value per award of RSA awards granted was $126.87, $148.35 and $172.95 during the years ended December 31, 2023, 2022 and 2021, respectively. The grant date fair value of RSAs that vested during the year was $3.3 million for the year ended December 31, 2023, $8.3 million for the year ended December 31, 2022 and $9.3 million for the year ended December 31, 2021. The fair value of RSAs as of their respective vesting dates was $2.6 million for the year ended December 31, 2023, $6.5 million for the year ended December 31, 2022 and $20.0 million for the year ended December 31, 2021.

For the years ended December 31, 2023, 2022 and 2021, the Company recorded, as compensation charges related to restricted stock awards and units issued to employees and non-employees, selling, general and administrative expense of $9.5 million, $14.3 million and $15.4 million, respectively, cost of sales of $1.9 million, $2.2 million and $2.5 million, respectively, and research and development expense of $5.8 million, $6.1 million and $5.2 million, respectively.

In connection with the vesting of restricted stock awards and units during the years ended December 31, 2023, 2022 and 2021, 53,162, 54,856 and 67,798 shares, respectively, with aggregate fair values of $7.4 million, $8.4 million and $14.1 million, respectively, were withheld in satisfaction of tax withholding obligations and are reflected as a financing activity within the Consolidated Statements of Cash Flows.

For the years ended December 31, 2023, 2022 and 2021, the Company recorded as compensation charges related to all restricted stock units to non-employee members of the Scientific Advisory Board, whose unvested shares are marked-to-market each reporting period, research and development expense of $248,000, $234,000 and $220,000, respectively.

The Company has granted restricted stock units to non-employee members of the Board of Directors with quarterly vesting over a period of approximately one year. The fair value is equal to the market price of the Company's common stock on the date of grant. The restricted stock units are issued and expense is recognized ratably over the vesting period. For the years ended December 31, 2023, 2022 and 2021, the Company recorded compensation charges for services performed, related to all restricted stock units granted to non-employee members of the Board of Directors, selling, general and administrative expense of $1.5 million, $1.3 million and $1.2 million, respectively. In connection with the vesting of the restricted stock, the Company issued to non-employee members of the Board of Directors 13,016, 8,784 and 5,412 shares during the years ended December 31, 2023, 2022 and 2021, respectively.

As of December 31, 2023, the total unrecognized expense related to all restricted stock awards and units was $21.7 million, which the Company expects to recognize over a weighted average period of 1.80 years.

Performance Unit Awards

Each performance unit award is subject to both a performance-vesting requirement (either performance-based or market-based) and a service-vesting requirement. The performance-based vesting requirement is tied to EBITDA and cash flow achievement, as measured over a specific performance period. The market-based vesting requirement is tied to the Company's total shareholder return (TSR) relative to the TSR of companies comprising the Nasdaq Electronics Components Index, as measured over a three-year performance period. The maximum number of performance units that may vest based on performance is three times the shares granted. Further, if the Company's performance falls below certain thresholds, the performance units will not vest at all.

The following table summarizes the activity related to performance unit awards (PSU) share based payment awards:


	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested, January 1, 2023		227,866		$	185.57
Granted		84,448			165.72
Vested		(11,970	)		155.85
Forfeited		(91,791	)		170.96
Unvested, December 31, 2023		208,553		$	185.86

During the years ended December 31, 2023, 2022 and 2021, the Company granted 84,448, 100,621 and 77,086 performance units, respectively, of which 63,335, 75,465 and 42,291 units, respectively, are subject to performance-based vesting requirements and 21,113, 25,156 and 34,795 units, respectively, are subject to market-based vesting requirements, and which will vest over the terms described above. During the years ended December 31, 2023, 2022 and 2021, there were none, 1,268, and none incremental performance-based shares, respectively, that vested resulting from an increased vesting factor based on Company performance. The weighted average grant date fair value per unit of the performance unit awards granted was $165.72, $186.66 and $214.70 during the years ended December 31, 2023, 2022 and 2021, respectively, as determined by the Company’s common stock on date of grant for the units with performance-based vesting and a Monte-Carlo simulation for the units with market-based vesting. The grant date fair value of PSUs that vested during the year was $1.9 million for the year ended December 31, 2023, $1.9 million for the year ended December 31, 2022 and $1.1 million for the year ended December 31, 2021. The fair value of PSUs as of their respective vesting dates was $1.7 million for the year ended December 31, 2023, $1.8 million for the year ended December 31, 2021 and $2.0 million for the year ended December 31, 2021.

For the years ended December 31, 2023, 2022 and 2021, the Company recorded, as compensation charges related to all performance stock units, selling, general and administrative expense of $2.6 million, $2.8 million and $8.0 million, respectively, cost of sales of $770,000, $940,000 and $1.3 million, respectively, and research and development expense of $1.2 million, $1.5 million and $2.1 million, respectively.

In connection with the vesting of performance units during the years ended December 31, 2023, 2022 and 2021, 5,350, 5,082 and 3,881 shares, respectively, with aggregate fair values of $775,000, $826,000 and $875,000, respectively, were withheld in satisfaction of tax withholding obligations and are reflected as a financing activity within the Consolidated Statements of Cash Flows.

As of December 31, 2023, the total unrecognized compensation expense related to performance unit awards was $12.9 million, which the Company expects to recognize over a weighted average period of 1.98 years.

Employee Stock Purchase Plan

On April 7, 2009, the Board of Directors of the Company adopted an Employee Stock Purchase Plan (ESPP). The ESPP was approved by the Company’s shareholders and became effective on June 25, 2009. The Company has reserved 1,000,000 shares of common stock for issuance under the ESPP. Unless terminated by the Board of Directors, the ESPP will expire when all reserved shares have been issued.

Eligible employees may elect to contribute to the ESPP through payroll deductions during consecutive three-month purchase periods, the first of which began on July 1, 2009. Each employee who elects to participate will be deemed to have been granted an option to purchase shares of the Company’s common stock on the first day of the purchase period. Unless the employee opts out during the purchase period, the option will automatically be exercised on the last day of the period, which is the purchase date, based on the employee’s accumulated contributions to the ESPP. The purchase price will equal 85% of the lesser of the closing price per share of common stock on the first day of the period or the last business day of the period.

Employees may allocate up to 10% of their base compensation to purchase shares of common stock under the ESPP; however, each employee may purchase no more than 12,500 shares on a given purchase date, and no employee may purchase more than $25,000 of common stock under the ESPP during a given calendar year.

For the years ended December 31, 2023, 2022 and 2021, the Company issued 17,513, 17,057 and 9,156 shares, respectively, of its common stock under the ESPP, resulting in proceeds of $2.0 million, $1.6 million and $1.5 million, respectively. For the years ended December 31, 2023, 2022 and 2021, the Company recorded charges of $136,000, $107,000 and $93,000, respectively, to selling, general and administrative expense, $167,000, $141,000, $119,000, respectively, to cost of sales and $240,000, $224,000 and $188,000, respectively, to research and development expense, related to the ESPP equal to the amount of the discount and the value of the look-back feature.

Scientific Advisory Board Awards

During the years ended December 31, 2023 and 2022, the Company granted a total of 2,366 and 2,024 shares, respectively, of fully vested common stock to non-employee members of the Scientific Advisory Board for services performed in 2022 and 2021, respectively. The fair value of the shares issued to members of the Scientific Advisory Board was $300,000 for both years ended December 31, 2023 and 2022.

EMPLOYEE RETIREMENT PLANS

12 Months Ended

Dec. 31, 2023

Defined Benefit Pension Plans And Defined Benefit Postretirement Plans [Abstract]

EMPLOYEE RETIREMENT PLANS

17.

EMPLOYEE RETIREMENT PLANS:

Defined Contribution Plan

The Company maintains the Universal Display Corporation 401(k) Plan (the Plan) in accordance with the provisions of Section 401(k) of the Internal Revenue Code (the Code). The Plan covers substantially all full-time employees of the Company. Participants may contribute up to 90% of their total compensation to the Plan, not to exceed the limit as defined in the Code. Once an employee is eligible to participate in the Plan, the Company will make a non-elective contribution equal to 3% of the employee’s total compensation. For the years ended December 31, 2023, 2022 and 2021, the Company contributed $1.5 million, $1.4 million and $1.3 million, respectively, to the Plan.

Defined Benefit Plan

On March 18, 2010, the Human Capital Committee and the Board of Directors of the Company approved and adopted the Universal Display Corporation Supplemental Executive Retirement Plan (SERP), effective as of April 1, 2010. On March 3, 2015, the Human Capital Committee and the Board of Directors amended the SERP to include salary and bonus as part of the plan. Prior to this amendment, the SERP benefit did not take into account any bonuses. The purpose of the SERP, which is unfunded, is to provide certain of the Company’s key employees with supplemental pension benefits following a cessation of their employment and to encourage their continued employment with the Company. As of December 31, 2023 there were eight participants in the SERP.

The SERP benefit is based on a percentage of the participant’s annual base salary and in certain cases, the participant's average annual bonus for the most recent three fiscal years ending prior to the participant's date of termination of employment with the Company for the life of the participant. For this purpose, annual base salary means 12 times the average monthly base salary paid or payable to the participant during the 24-month period immediately preceding the participant’s date of termination of employment, or, if required, the date of a change in control of the Company.

Under the SERP, if a participant resigns or is terminated without cause at or after age 65 and with at least 20 years of service, he or she will be eligible to receive a SERP benefit. The benefit is based on a percentage of the participant’s annual base salary and bonus for the life of the participant. This percentage is 50%, 25% or 15%, depending on the participant’s benefit class.

If a participant resigns at or after age 65 and with at least 15 years of service, he or she will be eligible to receive a prorated SERP benefit. If a participant is terminated without cause or on account of a disability after at least 15 years of service, he or she will be eligible to receive a prorated SERP benefit regardless of age. The prorated benefit in either case would be based on the participant’s number of years of service (up to 20), divided by 20. In the event a participant is terminated for cause, his or her SERP benefit and any future benefit payments are subject to immediate forfeiture.

The SERP benefit is payable in installments over 10 years, beginning at the later of age 65 or the date of the participant’s separation from service. Payments are based on a present value calculation of the benefit amount for the actuarial remaining life expectancy of the participant. This calculation is made as of the date benefit payments are to begin (later of age 65 or separation from service). If the participant dies after reaching age 65, any future or remaining benefit payments are made to the participant’s beneficiary or estate. If the participant dies before reaching age 65, the benefit is forfeited.

In the event of a change in control of the Company, each participant will become immediately vested in his or her SERP benefit. Unless the participant’s benefit has already fully vested, if the participant has less than 20 years of service at the time of the change in control, he or she will receive a prorated benefit based on his or her number of years of service (up to 20), divided by 20. If the change in control qualifies as a “change in control event” for purposes of Section 409A of the Internal Revenue Code, then each participant (including former employees who are entitled to SERP benefits) will receive a lump sum cash payment equal to the present value of the benefit immediately upon the change in control.

Certain of the Company’s executive officers are designated as special participants under the SERP. If these participants resign or are terminated without cause after 20 years of service, or at or after age 65 and with at least 15 years of service, they will be eligible to receive a SERP benefit. If they are terminated without cause or on account of a disability, they will be eligible to receive a prorated SERP benefit regardless of age. The prorated benefit would be based on the participant’s number of years of service (up to 20), divided by 20.

The SERP benefit for special participants is based on 50% of their annual base salary and bonus for their life and the life of their surviving spouse, if any. Payments are based on a present value calculation of the benefit amount for the actuarial remaining life expectancies of the participant and their surviving spouse, if any. If they die before reaching age 65, the benefit is not forfeited if the surviving spouse, if any, lives until the participant would have reached age 65. If their spouse also dies before the participant would have reached age 65, the benefit is forfeited.

The Company records amounts relating to the SERP based on calculations that incorporate various actuarial and other assumptions, including discount rates, rate of compensation increases, retirement dates, and life expectancies. The net periodic costs are recognized as employees render the services necessary to earn the SERP benefits.

In connection with the initiation and subsequent amendments of the SERP, the Company recorded cost related to prior service of $1.9 million as accumulated other comprehensive loss as of December 31, 2023. The prior service cost is being amortized as a component of net periodic pension cost over the average of the remaining service period of the employees expected to receive benefits under the plan. The prior service cost expected to be amortized for the year ending December 31, 2024 is $43,000. In December 2022, one of the participants retired and monthly SERP benefit payments commenced in January 2023. The total SERP benefit payments for the year ended December 31, 2023 were $2.0 million.

Information relating to the Company’s plan is as follows (in thousands):


	Year Ended December 31,
	2023			2022
Change in benefit obligation:
Benefit obligation, beginning of year	$	61,804		$	66,773
Service cost		951			1,287
Interest cost		2,898			1,383
Actuarial gain		(9,375	)		(7,639	)
Benefit payments		(2,015	)		—
Benefit obligation, end of year		54,263			61,804
Fair value of plan assets		—			—
Unfunded status of the plan, end of year	$	54,263		$	61,804
Current liability	$	2,014		$	2,014
Non-current liability	$	52,249		$	59,790

The accumulated benefit obligation for the plan was $52.5 million and $59.5 million as of December 31, 2023 and 2022, respectively. The actuarial gain of $9.4 million for the year ended December 31, 2023 was primarily due to a decrease in the total average annual bonus for each of the participants during the most recent three fiscal years. The actuarial gain of $7.6 million for the year ended December 31, 2022 was primarily due to an increase in the discount rate.

The components of net periodic pension cost were as follows (in thousands):


	Year Ended December 31,
	2023		2022		2021
Service cost	$	951	$	1,287	$	1,675
Interest cost		2,898		1,383		1,165
Amortization of prior service cost		815		1,119		1,099
Amortization of loss		480		1,487		4,936
Total net periodic benefit cost	$	5,144	$	5,276	$	8,875

The measurement date is the Company’s fiscal year end. The net periodic pension cost is based on assumptions determined at the prior year end measurement date.

Assumptions used to determine the year end benefit obligation were as follows:


	Year Ended December 31,
	2023			2022
Discount rate		4.74	%		4.94	%
Rate of compensation increases		3.50	%		3.50	%

Assumptions used to determine the net periodic pension cost were as follows:


	Year Ended December 31,
	2023			2022			2021
Discount rate		4.94	%		2.16	%		1.54	%
Rate of compensation increases		3.50	%		3.50	%		3.50	%

Actuarial gains and losses are amortized from accumulated other comprehensive loss into net periodic pension cost over future years based upon the average remaining service period of active plan participants, when the accumulation of such gains or losses exceeds 10% of the year end benefit obligation. The cost or benefit of plan changes that increase or decrease benefits for prior employee service (prior service cost or credit) is included in the Company’s results of income on a straight-line basis over the average remaining service period of active plan participants.

The estimated amounts to be amortized from accumulated other comprehensive loss into the net periodic pension cost in 2024 are as follows (in thousands):


Amortization of prior service cost	$	43
Amortization of loss		—
Total	$	43

Benefit payments, which reflect estimated future service, are currently expected to be paid as follows (in thousands):


Year	Projected Benefits
2024	$	2,014
2025		5,097
2026		6,141
2027		6,489
2028		6,489
2029-2033		34,503
Thereafter		14,855

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480266/715-60-50-3

+ Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

18.

COMMITMENTS AND CONTINGENCIES:

Commitments

Under the current research agreement with USC, the Company is obligated to make certain payments to USC based on work performed by it under that agreement, and by the University of Michigan (Michigan) under a subcontractor agreement that Michigan has with USC.

Under the terms of the current license agreement among the Company, Princeton and USC, the Company makes royalty payments to Princeton. See Note 11 for further explanation.

The Company has agreements with five executive officers and 13 senior level employees which provide for certain cash and other benefits upon termination of employment of the officer or employee in connection with a change in control of the Company. If a covered person’s employment is terminated in connection with the change in control, the person is entitled to a lump-sum cash payment equal to two times (in the case of the executive officers) or either one or two times (in the case of the senior level employees) the sum of the average annual base salary and bonus of the person and immediate vesting of all stock options and other equity awards that may be outstanding at the date of the change in control, among other items.

In order to manage manufacturing lead times and help ensure adequate material supply, the Company entered into the New OLED Materials Agreement (see Note 13) that allows PPG to procure and produce inventory based upon criteria as defined by the Company. These purchase commitments consist of firm, noncancelable and unconditional commitments. In certain instances, this agreement allows the Company the option to reschedule and adjust the Company’s requirements based on its business needs prior to firm orders being placed. As of December 31, 2023, 2022 and 2021, the Company had purchase commitments for inventory of $29.8 million, $31.9 million and $25.7 million, respectively.

Patent Related Challenges and Oppositions

Each major jurisdiction in the world that issues patents provides both third parties and applicants an opportunity to seek a further review of an issued patent. The process for requesting and considering such reviews is specific to the jurisdiction that issued the patent in question, and generally does not provide for claims of monetary damages or a review of specific claims of infringement. The conclusions made by the reviewing administrative bodies tend to be appealable and generally are limited in scope and applicability to the specific claims and jurisdiction in question.

The Company believes that opposition proceedings are frequently commenced in the ordinary course of business by third parties who may believe that one or more claims in a patent do not comply with the technical or legal requirements of the specific jurisdiction in which the patent was issued. The Company views these proceedings as reflective of its goal of obtaining the broadest legally permissible patent coverage permitted in each jurisdiction. Once a proceeding is initiated, as a general matter, the issued patent continues to be presumed valid until the jurisdiction’s applicable administrative body issues a final non-appealable decision. Depending on the jurisdiction, the outcome of these proceedings could include affirmation, denial or modification of some or all of the originally issued claims. The Company believes that as OLED technology becomes more established and its patent portfolio increases in size, so will the number of these proceedings.

CONCENTRATION OF RISK

12 Months Ended

Dec. 31, 2023

Risks and Uncertainties [Abstract]

CONCENTRATION OF RISK

19.

CONCENTRATION OF RISK:

Revenues and accounts receivable from the Company's largest customers for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):


	2023			2022			2021
Customer	% of Total Revenue	Accounts Receivable		% of Total Revenue	Accounts Receivable		% of Total Revenue	Accounts Receivable
A	36%	$	38,105	41%	$	11,425	44%	$	10,850
B	23%		30,142	25%		24,440	26%		45,867
C	17%		38,529	16%		22,291	14%		18,557

Revenues from outside of North America represented approximately 98%, 97%, and 97% of consolidated revenue for each of the years ended December 31, 2023, 2022 and 2021, respectively. Revenues by geographic area are as follows (in thousands):


	Year Ended December 31,
Country	2023		2022		2021
South Korea	$	322,509	$	360,640	$	334,835
China		229,727		230,582		192,079
Japan		6,971		5,579		7,358
Other non-U.S. locations		4,411		3,829		3,137
Total non-U.S. locations		563,618		600,630		537,409
United States		12,811		15,989		16,116
Total revenue	$	576,429	$	616,619	$	553,525

The Company attributes revenue to different geographic areas on the basis of the location of the customer.

Property and equipment, net by geographic area are as follows (in thousands):


	December 31,
Country	2023		2022
United States	$	118,250	$	117,255
Ireland		42,203		20,270
Other		14,697		5,920
Total long-lived assets	$	175,150	$	143,445

Substantially all chemical materials were purchased from one supplier. See Note 13.

INCOME TAXES

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

20.

INCOME TAXES:

The components of income before income taxes are as follows (in thousands):


	Year ended December 31,
	2023		2022		2021
United States	$	71,514	$	77,205	$	60,066
Foreign		173,657		191,025		168,181
Income before income taxes	$	245,171	$	268,230	$	228,247

The components of the income tax expense are as follows (in thousands):


	Year ended December 31,
	2023			2022			2021
Current income tax (expense) benefit:
Federal	$	(15,848	)	$	(51,980	)	$	(16,433	)
State		(3,048	)		(1,833	)		(641	)
Foreign		(27,030	)		(31,302	)		(25,212	)
		(45,926	)		(85,115	)		(42,286	)
Deferred income tax (expense) benefit:
Federal		(460	)		25,916			(844	)
State		3,936			1,216			(734	)
Foreign		290			(186	)		(170	)
		3,766			26,946			(1,748	)
Income tax expense	$	(42,160	)	$	(58,169	)	$	(44,034	)

Reconciliation of the statutory U.S. federal tax rate to the Company's effective tax rate is as follows:


	Year ended December 31,
	2023			2022			2021
Statutory U.S. federal income tax rate		21.0	%		21.0	%		21.0	%
Effect of foreign operations		(4.0	)		(4.9	)		(5.0	)
U.S. International Tax (Sub F, GILTI, FDII)		2.9			4.2			2.1
Research tax credits		(2.4	)		(1.9	)		(1.4	)
Redetermination of foreign tax credit utilization		(2.0	)		—			—
Nondeductible employee compensation		1.7			1.9			3.0
State income taxes, net of federal benefit		(0.2	)		0.1			0.2
Stock based compensation		0.1			0.2			(0.3	)
Accruals and reserves		—			—			(0.8	)
Other		0.1			1.1			0.5
Effective tax rate		17.2	%		21.7	%		19.3	%

The following table summarizes Company tax credit carry forwards for tax return purposes as of December 31, 2023 (in thousands):


	Tax Benefit		Expiration Date
Tax credit carry forwards:
State research tax credits	$	8,752	2034-2038
Foreign tax credits	$	186	2031
Total credit carry forwards	$	8,938

Significant components of the Company's net deferred tax assets and liabilities are as follows (in thousands):


	December 31,
	2023			2022
Deferred tax asset:
Capitalized research expenditures	$	39,459		$	38,485
Retirement plan		12,555			13,495
Tax credit carry forwards		8,938			8,100
Accruals and reserves		7,180			6,944
Lease Liabilities		6,671			7,230
Deferred revenue		1,741			2,077
Stock-based compensation		1,498			1,454
Other		1,362			3,400
		79,404			81,185
Valuation allowance		(9,551	)		(11,087	)
Deferred tax assets		69,853			70,098
Deferred tax liability:
Lease Assets		(6,302	)		(6,944	)
Acquisition Goodwill		(1,549	)		(1,283	)
Other		(2,894	)		(3,710	)
Deferred tax liabilities		(10,745	)		(11,937	)
Net deferred tax assets	$	59,108		$	58,161

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent on the Company's ability to generate future taxable income to obtain benefit from the reversal of temporary differences, net operating loss carryforwards and tax credits. As part of its assessment, management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. At this time there is not sufficient evidence to release the valuation allowance that has been recorded for the New Jersey research and development credits and unrealized loss on investments. There are no indicators against the realizability of the remaining net deferred tax asset.

The U.S.-Korean Mutual Agreement Procedure (MAP) for the years ended December 31, 2010, to December 31, 2017, was closed in September 2022, resulting in a refund of the Korean withholding taxes previously withheld. The Company filed amended U.S. federal tax returns to reflect the refund and to redetermine the foreign tax credit amount. As a result, the Company has recorded a long-term asset of $3.0 million in the year ended December 31, 2022. There was no long-term asset recorded for the year ended December 31, 2023.

On December 27, 2018, the Korean Supreme Court, citing prior cases, held that only royalties paid with respect to Korean registered patents are considered Korean source income and subject to Korean withholding tax under the applicable law and interpretation of the Korea-U.S. Tax Treaty. The Company has incurred Korean withholding tax of $14.9 million for each of the years ended December 31, 2018, through December 31, 2022. Based on the Korean Supreme Court decision, a tax refund request on behalf of the Company was or will be filed with the Korean National Tax Service (KNTS) for the entire period from January 1, 2018, to December 31, 2022. The Company received a formal rejection from the KNTS; and in May 2022 filed an appeal with the Korean Tax Tribunal. On December 18th, 2023, the Company received a formal rejection from the Tax Tribunal. Anticipating the rejection of the appeal, in September 2023 the Company filed a petition to the District Court and is awaiting its decision. The Company has been advised by a prominent Korean law firm that there is a more-likely-than-not chance of success. As a result, the Company has recorded a long-term asset of $60.1 million and $60.9 million as of December 31, 2023, and December 31, 2022, respectively for the receipt of the Korean withholding tax. The Company also recorded foreign exchange loss of $732,000 during the year ended December 31, 2023, due to the fluctuation of the Korean Won to the U.S. Dollar and resulting remeasurement of this Won-denominated receivable. The Company will amend U.S. federal tax returns for the 2018 to 2022 years when the anticipated refund from KNTS is received to offset the additional tax liability. The Company has recorded a long-term liability of $15.7 million and $14.6 million as of December 31, 2023, and December 31, 2022, respectively, for the estimated amounts due to the U.S. federal government based on the amendment of the Company's U.S. tax returns, indicating that lower withholding amounts were required.

The Company is not subject to examinations by the federal tax authority for the years prior to 2017. The Company's state and foreign tax returns are open for a period of generally three to four years. The Company is under California tax audit for 2019 and 2020 years, which is in the information-collecting stage.

The above estimates may change in the future and upon settlement.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

REVENUE RECOGNITION

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

21.

REVENUE RECOGNITION:

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (Topic 606). The standard establishes the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows from a contract with a customer.

For each of the years ended December 31, 2023, 2022 and 2021, the Company recorded 97% of its revenue from OLED related sales and 3% from the providing of services through Adesis, respectively.

Contract Balances

The following table provides information about assets and liabilities associated with the Company's contracts from customers (in thousands):


	As of December 31, 2023
Accounts receivable	$	139,850
Short-term unbilled receivables		21,084
Short-term contract assets		2,698
Long-term unbilled receivables		9,074
Long-term contract assets		9,278
Short-term deferred revenue		47,713
Long-term deferred revenue		12,006

Short-term and long-term unbilled receivables and contract assets are classified as other current assets and other assets, respectively, on the Consolidated Balance Sheets. Contract assets represent consideration related to the renewal of customer contracts which is recognized over the contract term based on material units sold. The deferred revenue balance as of December 31, 2023 will be recognized as materials are shipped to customers over the remaining contract periods. As of December 31, 2023, the Company had $25.2 million of backlog associated with committed purchase orders from its customers for phosphorescent emitter material. These orders are anticipated to be fulfilled within the next 90 days.

Significant changes in the assets and liabilities balances associated with the Company's contracts from customers for the years ended December 31, 2023 and 2022, are as follows (in thousands):


	Year Ended December 31, 2023
	Assets			Liabilities
Balance at December 31, 2022	$	38,457		$	(63,878	)
Revenue recognized that was previously included in deferred revenue, net		—			195,703
Increases due to cash received		—			(202,100	)
Cumulative catch-up adjustment arising from changes in estimates of transaction price, net		—			10,556
Unbilled receivables recorded, net		41,659			—
Contract assets recorded, net		(2,407	)		—
Transferred to receivables from unbilled receivables		(35,575	)		—
Net change		3,677			4,159
Balance at December 31, 2023	$	42,134		$	(59,719	)

	Year Ended December 31, 2022
	Assets			Liabilities
Balance at December 31, 2021	$	8,127		$	(157,081	)
Revenue recognized that was previously included in deferred revenue, net		—			239,608
Increases due to cash received		—			(176,667	)
Cumulative catch-up adjustment arising from changes in estimates of transaction price, net		—			30,262
Unbilled receivables recorded, net		15,946			—
Contract assets recorded, net		14,384			—
Net change		30,330			93,203
Balance at December 31, 2022	$	38,457		$	(63,878	)

The cumulative catch-up adjustment arising from changes in estimates of transaction price, net was $10.6 million for the year ended December 31, 2023 as compared to $30.3 million for the year ended December 31, 2022. These adjustments resulted from an increase in the average price per gram that was primarily due to the decrease in anticipated demand by several of the Company's customers over the remaining lives of their contracts, resulting from changes in global macroeconomic factors.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

NET INCOME PER COMMON SHARE

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

NET INCOME PER COMMON SHARE

22.

NET INCOME PER COMMON SHARE:

The Company computes earnings per share in accordance with ASC Topic 260, Earnings per Share, which requires earnings per share (EPS) for each class of stock to be calculated using the two-class method. The two-class method is an allocation of income between the holders of common stock and the Company's participating security holders. Under the two-class method, income for the reporting period is allocated between common shareholders and other security holders based on their respective participation rights in undistributed income. Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and, therefore, are included in computing earnings per share pursuant to the two-class method.

Basic net income per common share is computed by dividing net income allocated to common shareholders by the weighted-average number of shares of common stock outstanding for the period excluding unvested restricted stock units and performance units. Net income allocated to the holders of the Company's unvested restricted stock awards is calculated based on the shareholders proportionate share of weighted average shares of common stock outstanding on an if-converted basis.

For purposes of determining diluted net income per common share, basic net income per share is further adjusted to include the effect of potential dilutive common shares outstanding, including restricted stock units, performance units and the impact of shares to be issued under the Company's Employee Stock Purchase Plan.

The following table is a reconciliation of net income and the shares used in calculating basic and diluted net income per common share for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share data):


	Year Ended December 31,
	2023			2022			2021
Numerator:
Net income	$	203,011		$	210,061		$	184,213
Adjustment for Basic EPS:
Earnings allocated to unvested shareholders		(993	)		(1,215	)		(1,137	)
Adjusted net income	$	202,018		$	208,846		$	183,076
Denominator:
Weighted average common shares outstanding – Basic		47,559,669			47,390,352			47,296,447
Effect of dilutive shares:
Common stock equivalents arising from stock options and ESPP		2,173			2,340			1,010
Restricted stock awards and units and performance units		60,921			75,815			67,978
Weighted average common shares outstanding – Diluted		47,622,763			47,468,507			47,365,435
Net income per common share:
Basic	$	4.25		$	4.41		$	3.87
Diluted	$	4.24		$	4.40		$	3.87

For the years ended December 31, 2023, 2022, and 2021, the combined effects of unvested restricted stock awards, restricted stock units, performance unit awards and stock options of 36,345, 122,843 and none, respectively, were excluded from the calculation of diluted EPS as their impact would have been antidilutive.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of Universal Display Corporation and its wholly owned subsidiaries, UDC, Inc., UDC Ireland Limited (UDC Ireland), Universal Display Corporation Hong Kong, Limited, Universal Display Corporation Korea, Y.H. (UDC Korea), Universal Display Corporation Japan GK, Universal Display Corporation China, Ltd., Adesis, Inc. (Adesis), UDC Ventures LLC, OVJP Corporation (OVJP Corp) and OLED Material Manufacturing Limited (OMM). All intercompany transactions and accounts have been eliminated.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year adjustments to reconcile net income to net cash provided by operating activities have been reclassified on the Consolidated Statements of Cash Flows to conform to the current year presentation. These adjustments have been consolidated into their respective operating assets and liabilities accounts, specifically, inventory, other current assets, other assets and deferred revenue.
Management's Use of Estimates	Management’s Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates made are principally in the areas of revenue recognition including estimates of material unit sales and royalties, the useful life of acquired intangibles, lease liabilities, right-of-use assets, the use and recoverability of inventories, intangibles, investments and income taxes including realization of deferred tax assets, stock-based compensation and retirement benefit plan liabilities. Actual results could differ from those estimates.
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments The Company considers all highly liquid debt instruments purchased with an original maturity (maturity at the purchase date) of three months or less to be cash equivalents. The Company classifies its remaining investments as available-for-sale. These securities (excluding minority equity investments) are carried at fair market value, with unrealized gains and losses reported in shareholders’ equity. Gains or losses on securities sold are based on the specific identification method.
Trade Accounts Receivable	Trade Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is a result of chemical sales, royalties and license fees. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant collection risk. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for credit losses would be required. As of December 31, 2023 and 2022, the allowance for credit losses was $166,000 and $279,000, respectively.
Inventories	Inventories Inventories consist of raw materials, work-in-process and finished goods, and are stated at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory valuation and firm committed purchase order assessments are performed on a quarterly basis and those items that are identified to be obsolete or in excess of forecasted usage are written down to their estimated realizable value. Estimates of realizable value are based upon management’s analyses and assumptions, including, but not limited to, forecasted sales levels by product, expected product lifecycle, product development plans and future demand requirements. A 12-month rolling forecast based on factors, including, but not limited to, production cycles, anticipated product orders, marketing forecasts, backlog, and shipment activities is used in the inventory analysis. If market conditions are less favorable than forecasts or actual demand from customers is lower than estimates, additional inventory write-downs may be required. If demand is higher than expected, inventories that had previously been written down may be sold.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful life of 30 years for buildings, 15 years for building improvements, and three to seven years for office and lab equipment and furniture and fixtures. Repair and maintenance costs are charged to expense as incurred. Additions and betterments are capitalized. Major renewals and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to current operations as incurred. Upon retirement or disposal of assets, the cost and related accumulated depreciation are removed from the Consolidated Balance Sheets and any gain or loss is reflected in other operating expenses. Certain costs of computer software obtained for internal use are capitalized and amortized on a straight-line basis over three years. Costs for maintenance and training, as well as the cost of software that does not add functionality to an existing system, are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Company management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2023, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the years ended December 31, 2022 or 2021.
Goodwill and Purchased Intangible Assets	Goodwill and Purchased Intangible Assets Goodwill is tested for impairment in the fourth fiscal quarter and, when specific circumstances dictate, between annual tests. If after assessing the totality of events or circumstances as those described in the qualitative assessment, it is determined that it is more likely than not the fair value of a reporting unit is less than its carrying amount, then a quantitative goodwill impairment test will be performed. Under the quantitative test, the fair value of the reporting unit is compared to its carrying amount including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit would be considered not impaired. However, if the carrying amount of the reporting unit exceeds its fair value, an impairment loss would be recognized in the amount equal to the excess, limited to the total amount of goodwill allocated to that reporting unit. The Company performed its annual impairment assessment as of December 31, 2023 utilizing a qualitative assessment and concluded that it was more likely than not that the fair value of Adesis is greater than its carrying value. Future impairment tests will continue to be performed annually in the fiscal fourth quarter, or sooner if a triggering event occurs. As of December 31, 2023, no indications of impairment existed. Purchased intangible assets with finite lives are carried at cost, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value in the accompanying Consolidated Financial Statements due to the short-term nature of those instruments. The Company’s other financial instruments, which include cash equivalents and investments (excluding minority equity investments) are carried at fair value.
Fair Value Measurements	Fair Value Measurements Fair value is defined as an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. The Company uses valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability and are based on market data obtained from sources independent of the Company. Unobservable inputs reflect assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Minority Equity Investments	Minority Equity Investments The Company accounts for minority equity investments in companies that are not accounted for under the equity method as equity securities without readily determinable fair values. The value of these securities is based on original cost less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment in the same issuer. Under this method, the share of income or loss of such companies is not included in the Consolidated Statements of Income. The carrying value of these investments is included in investments on the Consolidated Balance Sheets. The Company’s policy is to recognize an impairment in the value of its minority equity investments when evidence of an impairment exists. Factors considered in the assessment include a significant adverse change in the regulatory, economic, or technological environment, the completion of new equity financing that may indicate a decrease in value, the failure to complete new equity financing arrangements after seeking to raise additional funds, or the commencement of proceedings under which the assets of the business may be placed in receivership or liquidated to satisfy the claims of debt and equity stakeholders. The impairment in the value of minority equity investments is included in the other (loss) income, net line item on the Consolidated Statements of Income.
Leases	Leases The Company is a lessee in operating leases primarily incurred to facilitate manufacturing, research and development, and selling, general and administrative activities. At contract inception, the Company determines if an arrangement is or contains a lease, and if so recognizes a right-of-use asset and lease liability at the lease commencement date. For operating leases, the lease liability is measured at the present value of the unpaid lease payments at the lease commencement date, whereas for finance leases, the lease liability is initially measured at the present value of the unpaid lease payments and subsequently measured at amortized cost using the interest method. Operating lease right-of-use assets are included in other assets on the Consolidated Balance Sheets. The short-term portion of operating lease liabilities is included in other current liabilities on the Consolidated Balance Sheets and the long-term portion is included in other liabilities on the Consolidated Balance Sheets. As of December 31, 2023, the Company had no leases that qualified as financing arrangements. Key estimates and judgments include how the Company determines the discount rate used to discount the unpaid lease payments to present value and the lease term. The Company monitors for events or changes in circumstances that could potentially require recognizing an impairment loss.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue Material sales relate to the Company’s sale of its OLED materials for incorporation into its customers’ commercial OLED products or for their OLED development and evaluation activities. Revenue associated with material sales is generally recognized at the time title passes, which is typically at the time of shipment or at the time of delivery, depending upon the contractual agreement between the parties. Revenue may be recognized after control of the material passes in the event the transaction price includes variable consideration. For example, a customer may be provided an extended opportunity to stock materials prior to use in mass production and given a general right of return not conditioned on breaches of warranties associated with the specific product. In such circumstances, revenue will be recognized at the earlier of the expiration of the customer’s general right of return or once it becomes unlikely that the customer will exercise its right of return. The vast majority of revenue attributed to material sales is determined through technology license agreements and material supply agreements the terms of which are jointly agreed upon with the Company’s customers. The remaining revenue recognized is in the form of contract research services revenue earned by the Company’s subsidiary, Adesis, Inc., and the Company’s occasional material sales to smaller customers. None of the revenue recognized during the years ended December 31, 2023, 2022 or 2021 resulted solely from royalty or license fee arrangements as to which there were not associated material sales. The rights and benefits to the Company’s OLED technologies are conveyed to the customer through technology license agreements and material supply agreements. The Company believes that the licenses and materials sold under these combined agreements are not distinct from each other for financial reporting purposes and as such, they are accounted for as a single performance obligation. Accordingly, total contract consideration is estimated and recognized over the contract term based on material units sold at the estimated per unit fee over the life of the contract. Total contract consideration is allocated to material sales and royalty and licensing fees on the Consolidated Statements of Income based on contract pricing. Various estimates are relied upon to recognize revenue. The Company estimates total material units to be purchased by its customers over the contract term based on historical trends, industry estimates and its forecast process. Management uses the expected value method to estimate the material per unit fee. Additionally, management estimates the sales-based portion of royalty revenue based on the estimated net sales revenue of its customers over the contract term. Contract research services revenue is revenue earned by Adesis by providing chemical materials synthesis research, development and commercialization for non-OLED applications on a contractual basis. These services range from intermediates for structure-activity relationship studies, reference agents and building blocks for combinatorial synthesis, re-synthesis of key intermediates, specialty organic chemistry needs, and selective toll manufacturing. These services are provided to third-party pharmaceutical and life sciences firms and other technology firms at fixed costs or predetermined rates on a contract basis. Revenue is recognized as services are performed with billing schedules and payment terms negotiated on a contract-by-contract basis. Payments received in excess of revenue recognized are recorded as deferred revenue. In other cases, services may be provided and revenue is recognized before the customer is invoiced. In these cases, revenue recognized will exceed amounts billed and the difference, representing amounts which are currently unbillable to the customer pursuant to contractual terms, is recorded as an unbilled receivable. Technology development and support revenue is revenue earned from development and technology evaluation agreements and commercialization assistance fees. Technology development and support revenue is included in contract research services on the Consolidated Statements of Income. On December 2, 2022, the Company entered into a commercial patent license agreement with Samsung Display Co., Ltd. (SDC), replacing a previous license agreement that had been in place since 2018. This agreement, which covers the manufacture and sale of specified OLED display materials, was effective as of January 1, 2023 and lasts through the end of 2027 with an additional two-year extension option for SDC. Under this agreement, the Company is being paid a license fee, which includes quarterly and annual payments over the agreement term of five years. The agreement conveys to SDC the non-exclusive right to use certain of the Company's intellectual property assets for a limited period of time that is less than the estimated life of the assets. At the same time the Company entered into the current commercial license agreement with SDC, the Company also entered into a new supplemental material purchase agreement with SDC, which lasts for the same term as the license agreement and is subject to the same extension option. This new material purchase agreement replaced a previous purchase agreement that had been in place since 2018. Under the supplemental material purchase agreement, SDC agrees to purchase red and green phosphorescent emitter materials from the Company for use in the manufacture of licensed products. This amount purchased is subject to SDC’s requirements for phosphorescent emitter materials and the Company’s ability to meet these requirements over the term of the supplemental agreement. In 2015, the Company entered into an OLED patent license agreement and an OLED commercial supply agreement with LG Display Co., Ltd. (LG Display), which were effective as of January 1, 2015. The terms of these agreements were extended by a January 1, 2021 amendment through the end of 2025. The patent license agreement provides LG Display a non-exclusive, royalty bearing portfolio license to make and sell OLED displays under the Company's patent portfolio. The patent license calls for license fees, prepaid royalties and running royalties on licensed products. The OLED commercial supply agreement provides for the sale of materials for use by LG Display, which may include phosphorescent emitters and host materials. The agreements provide for certain other minimum obligations relating to the volume of material sales anticipated over the lives of the agreements as well as minimum royalty revenue. In 2023, the Company entered into new long-term, multi-year agreements with BOE Technology Group Co., Ltd. (BOE). Under these agreements, the Company has granted BOE non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The Company supplies phosphorescent OLED materials to BOE for use in its licensed products. In 2019, the Company entered into an evaluation and commercial supply relationship with Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. (CSOT). In 2020, the Company entered into long-term, multi-year agreements with CSOT. Under these agreements, the Company has granted CSOT non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The Company also supplies phosphorescent OLED materials to CSOT for use in its licensed products. In 2018, the Company entered into long-term, multi-year OLED patent license and material purchase agreements with Visionox Technology, Inc. (Visionox). Under the license agreement, the Company granted certain of Visionox’s affiliates non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The license agreement calls for license fees and running royalties on licensed products. Additionally, the Company supplies phosphorescent OLED materials to Visionox for use in its licensed products. In 2021, the Company announced that it had extended the Visionox agreement by entering into new five-year OLED material supply and license agreements with a new affiliate of Visionox, Visionox Hefei Technology Co. Ltd. In 2016, the Company entered into long-term, multi-year OLED patent license and material purchase agreements with Tianma Micro-electronics Co., Ltd. (Tianma). Under the license agreement, the Company has granted Tianma non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The license agreement calls for license fees and running royalties on licensed products. Additionally, the Company supplies phosphorescent OLED materials to Tianma for use in its licensed products. In 2021, the parties extended the terms of both the patent license and material purchase agreements for an additional multi-year-term. All material sales transactions that are not variable consideration transactions are billed and due within 90 days and substantially all are transacted in U.S. dollars.
Cost of Sales	Cost of Sales Cost of sales consists of labor and material costs associated with the production of materials processed at the facilities of the Company's manufacturing partner, PPG Industries, Inc. (PPG) and at the Company's internal facilities. The Company’s portion of cost of sales also includes depreciation of manufacturing equipment, as well as manufacturing overhead costs and inventory adjustments for excess and obsolete inventory.
Research and Development	Research and Development Expenditures for research and development are charged to expense as incurred.
Patent Costs	Patent Costs Costs associated with patent applications, patent prosecution, patent defense and the maintenance of patents are charged to expense as incurred. Costs to successfully defend a challenge to a patent are capitalized to the extent of an evident increase in the value of the patent. Costs that relate to an unsuccessful outcome are charged to expense.
Amortization of Acquired Technology	Amortization of Acquired Technology Amortization costs primarily relate to technology acquired from Merck KGaA, Darmstadt, Germany (Merck KGaA), BASF SE (BASF) and Fujifilm Corporation (Fujifilm). The Merck KGaA acquisition was completed on April 28, 2023. The BASF and Fujifilm acquisitions were completed in the years ended December 31, 2016 and 2012, respectively. Acquisition costs are being amortized over a period of 10 years for the Merck KGaA and BASF patents. The Fujifilm acquired technology was fully amortized over a period of 10 years that ended in July 2022.
Amortization of Other Intangible Assets	Amortization of Other Intangible Assets Other intangible assets from the Adesis acquisition are being amortized over a period of 10 to 15 years. See Note 7 for further discussion.
Translation of Foreign Currency Financial Statements and Foreign Currency Transactions	Translation of Foreign Currency Financial Statements and Foreign Currency Transactions The Company’s reporting currency is the U.S. dollar. The functional currency for the UDC Ireland and UDC Korea subsidiaries are also the U.S. dollar and the functional currency for the OMM subsidiary and each of the Company's other Asia-Pacific foreign subsidiaries is its respective local currency. The Company translates the amounts included in the Consolidated Statements of Income from OMM and its Asia-Pacific foreign subsidiaries into U.S. dollars at weighted-average exchange rates, which the Company believes are representative of the actual exchange rates on the dates of the transactions. The Company's OMM subsidiary and each of the Company's other Asia-Pacific foreign subsidiaries' assets and liabilities are translated into U.S. dollars from the local currency at the actual exchange rates as of the end of each reporting date, and the Company records the resulting foreign exchange translation adjustments in the Consolidated Balance Sheets as a component of accumulated other comprehensive loss. The overall effect of the translation of foreign currency and foreign currency transactions to date has been insignificant.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount of which the likelihood of realization is greater than 50%. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties, if any, related to unrecognized tax benefits as a component of tax expense.
Share-Based Payment Awards	Share-Based Payment Awards The Company recognizes in the Consolidated Statements of Income the grant-date fair value of equity-based awards such as shares issued under employee stock purchase plans, restricted stock awards, restricted stock units and performance unit awards issued to employees and directors. The grant-date fair value of stock awards is based on the closing price of the stock on the date of grant. The fair value of share-based awards is recognized as compensation expense on a straight-line basis over the requisite service period, net of forfeitures. The Company issues new shares upon the respective grant, exercise or vesting of the share-based payment awards, as applicable. Performance unit awards are subject to either a performance-based or market-based vesting requirement. For performance-based vesting, the grant-date fair value of the award, based on fair value of the Company's common stock, is recognized over the service period based on an assessment of the likelihood that the applicable performance goals will be achieved, and compensation expense is periodically adjusted based on actual and expected performance. Compensation expense for performance unit awards with market-based vesting is calculated based on the estimated fair value as of the grant date utilizing a Monte Carlo simulation model and is recognized over the service period on a straight-line basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Adoption of New Accounting Standards In October 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with FASB ASC 606. The adoption of ASU 2021-08, beginning on January 1, 2023, did not have a impact on the Consolidated Financial Statements and related disclosures. In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, Liabilities—Supplier Finance Programs (Subtopic 450-50): Disclosure of Supplier Finance Program Obligations, which require disclosures about a buyer's supplier finance program. The adoption of ASU 2022-04, beginning on January 1, 2023, did not have a impact on the Consolidated Financial Statements and related disclosures. Accounting Standards Issued But Not Yet Adopted In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. Under this standard, a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective January 1, 2024, and will not have a significant impact on the Consolidated Financial Statements and related disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The standard improves the reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 becomes effective January 1, 2024, and the Company is evaluating the potential impact of this standard on the Consolidated Financial Statements and related disclosures. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The standard enhances to the annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity's worldwide operations. ASU 2023-09 becomes effective January 1, 2025, and the Company is evaluating the potential impact of this standard on its income tax disclosures.

CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2023

Cash and Cash Equivalents [Abstract]

Schedule of Cash, Cash Equivalents

The following table provides details regarding the Company’s portfolio of cash and cash equivalents (in thousands):


	Amortized		Unrealized				Aggregate Fair
Cash and Cash Equivalents Classification	Cost		Gains		(Losses)		Market Value
December 31, 2023
Cash accounts in banking institutions	$	91,717	$	—	$	—	$	91,717
Money market accounts		268		—		—		268
	$	91,985	$	—	$	—	$	91,985
December 31, 2022
Cash accounts in banking institutions	$	86,268	$	—	$	—	$	86,268
Money market accounts		7,162		—		—		7,162
	$	93,430	$	—	$	—	$	93,430

Schedule of Investments

The following table provides details regarding the Company’s portfolio of short-term investments (in thousands):


	Amortized		Unrealized					Aggregate Fair
Short-term Investments Classification	Cost		Gains		(Losses)			Market Value
December 31, 2023
Corporate bonds	$	1,763	$	1	$	(5	)	$	1,759
U.S. Government bonds		420,769		303		(694	)		420,378
	$	422,532	$	304	$	(699	)	$	422,137
December 31, 2022
Corporate bonds	$	150,698	$	—	$	(910	)	$	149,788
U.S. Government bonds		339,472		32		(4,947	)		334,557
	$	490,170	$	32	$	(5,857	)	$	484,345

The following table provides details regarding the Company’s portfolio of long-term investments (in thousands):


	Amortized		Unrealized					Aggregate Fair
Long-term Investments Classification	Cost		Gains		(Losses)			Market Value
December 31, 2023
U.S. Government bonds	$	284,053	$	1,457	$	(8	)	$	285,502
	$	284,053	$	1,457	$	(8	)	$	285,502
December 31, 2022
Corporate bonds	$	2,479	$	—	$	(28	)	$	2,451
U.S. Government bonds		247,464		52		(2,152	)	$	245,364
	$	249,943	$	52	$	(2,180	)	$	247,815

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

+ Details

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2023 (in thousands):


			Fair Value Measurements, Using
	Total Carrying Value as of December 31, 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	268	$	268	$	—	$	—
Short-term Corporate bonds		1,759		1,759		—		—
Short-term U.S. Government bonds		420,378		420,378		—		—
Long-term U.S. Government bonds		285,502		285,502		—		—

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 (in thousands):


			Fair Value Measurements, Using
	Total Carrying Value as of December 31, 2022		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	7,162	$	7,162	$	—	$	—
Short-term Corporate bonds		149,788		149,788		—		—
Short-term U.S. Government bonds		334,557		334,557		—		—
Long-term Corporate bonds		2,451		2,451		—		—
Long-term U.S. Government bonds		245,364		245,364		—		—

INVENTORY (Tables)

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consisted of the following (in thousands):


	December 31,
	2023		2022
Raw materials	$	113,400	$	115,448
Work-in-process		9,433		7,626
Finished goods		52,962		60,146
Inventory	$	175,795	$	183,220

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment, net consist of the following (in thousands):


	December 31,
	2023			2022
Land	$	12,230		$	2,642
Building and improvements		116,903			99,586
Office and lab equipment		148,465			129,697
Furniture, fixtures and computer related assets		18,970			18,071
Construction-in-progress		22,490			10,567
		319,058			260,563
Less: Accumulated depreciation		(143,908	)		(117,118	)
Property and equipment, net	$	175,150		$	143,445

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2023

Finite-Lived Intangible Assets, Net [Abstract]

Schedule of Acquired Technology


	December 31,
	2023 (1)			2022
PD-LD, Inc.	$	—		$	1,481
Motorola		—			15,909
Merck KGaA		66,012			—
BASF		95,989			95,989
Fujifilm		109,462			109,462
Other		5,712			5,212
		277,175			228,053
Less: Accumulated amortization		(186,850	)		(189,671	)
Acquired technology, net	$	90,325		$	38,382

(1)

During the year ended December 31, 2023, the gross value and accumulated amortization associated with the PD-LD, Inc. and Motorola patent portfolios have been removed from the table as the underlying patents have reached the end of their useful lives.

Schedule of Other Intangible Assets

At December 31, 2023, these other intangible assets consist of the following (in thousands):


	December 31, 2023
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Customer relationships	$	10,520	$	(6,801	)	$	3,719
Developed IP, processes and recipes		4,820		(2,388	)		2,432
Trade name/Trademarks		1,500		(1,118	)		382
Other		448		(107	)		341
Total identifiable other intangible assets	$	17,288	$	(10,414	)	$	6,874

OTHER ASSETS (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure Text Block [Abstract]

Other Asset

Other assets consist of the following (in thousands):


	December 31,
	2023		2022
Long-term taxes receivable	$	60,146	$	63,915
Right-of-use assets		24,910		31,486
Long-term unbilled receivables		9,074		—
Long-term contract assets		9,278		11,651
Other long-term assets		1,881		2,687
Other assets	$	105,289	$	109,739

LEASES (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Summary of Operating Lease Cost and Supplemental Cash Flow Information Related to Operating Leases


	Year Ended December 31,
	2023		2022		2021
Operating lease cost	$	4,639	$	4,436	$	3,637
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	$	1,072	$	4,750	$	26,174

Schedule Of Operating Lease Right of Use Assets and Liabilities

The following table presents the Company’s operating lease right-of-use assets and liabilities (in thousands):


	December 31,
	2023		2022
Right-of-use assets	$	24,910	$	31,486
Short-term lease liabilities		3,533		3,737
Long-term lease liabilities		22,855		29,039

Schedule of Weighted Average Assumptions Used to Compute Right-of-use Assets and Lease Liabilities

The following table presents weighted average assumptions used to compute the Company’s right-of-use assets and lease liabilities:


	December 31, 2023
Weighted average remaining lease term (in years)		6.7
Weighted average discount rate		3.7	%

Schedule of Undiscounted Future Minimum Lease Payments Having Non-cancelable Lease Terms

Undiscounted future minimum lease payments as of December 31, 2023, by year and in the aggregate, having non-cancelable lease terms in excess of one year were as follows (in thousands):


	Maturities of
	Operating Lease Liabilities
2024	$	4,267
2025		4,321
2026		4,401
2027		4,323
2028		3,996
Thereafter		8,083
Total lease payments		29,391
Less: imputed interest		(3,003	)
Present value of lease payments	$	26,388

ACCRUED EXPENSES (Tables)

12 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following (in thousands):


	December 31,
	2023		2022
Compensation	$	29,456	$	31,751
PPG Industries, Inc. agreement		11,962		9,864
Consulting		2,121		910
Professional fees		1,124		906
Research and development agreements		822		662
Royalties		647		877
Other		5,948		6,032
Accrued expenses	$	52,080	$	51,002

OTHER LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2023

Other Liabilities [Abstract]

Schedule of other liabilities

Other liabilities consist of the following (in thousands):


	December 31,
	2023		2022
Long-term lease liabilities	$	22,855	$	29,039
Long-term taxes payable		15,749		14,592
Other long-term liabilities		54		54
Other liabilities	$	38,658	$	43,685

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

12 Months Ended

Dec. 31, 2023

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Loss

Amounts related to the changes in accumulated other comprehensive loss were as follows (in thousands):


	Unrealized Gain (Loss) on Available-for- Sale-Securities			Net Unrealized Gain (Loss) on Retirement Plan (2)			Change in Cumulative Foreign Currency Translation Adjustment			Total			Affected Line items in the Consolidated Statements of Income
Balance January 1, 2021, net of tax	$	91		$	(36,075	)	$	(35	)	$	(36,019	)
Other comprehensive (loss) gain before reclassification		(233	)		13,620			(39	)		13,348
Plan amendment cost		—			(283	)		—			(283	)
Reclassification to net income (1)		—			4,719			—			4,719		Selling, general and administrative, research and development and cost of sales
Change during period		(233	)		18,056			(39	)		17,784
Balance December 31, 2021, net of tax		(142	)		(18,019	)		(74	)		(18,235	)
Other comprehensive (loss) gain before reclassification		(7,745	)		5,971			(480	)		(2,254	)
Reclassification to net income (1)		—			2,037			—			2,037		Selling, general and administrative, research and development and cost of sales
Change during period		(7,745	)		8,008			(480	)		(217	)
Balance December 31, 2022, net of tax		(7,887	)		(10,011	)		(554	)		(18,452	)
Other comprehensive (loss) gain before reclassification		8,745			7,207			418			16,370
Reclassification to net income (1)		—			996			—			996		Selling, general and administrative, research and development and cost of sales
Change during period		8,745			8,203			418			17,366
Balance December 31, 2023, net of tax	$	858		$	(1,808	)	$	(136	)	$	(1,086	)

(1)

The Company reclassified amortization of prior service cost, actuarial loss and plan amendment cost for its retirement plan from accumulated other comprehensive loss to net income of $1.0 million, $2.0 million and $4.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.

Refer to Note 17: Employee Retirement Plans

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Restricted Stock and Units Activity

The following table summarizes the activity related to restricted stock unit (RSU) share based payment awards:


	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested, January 1, 2023		230,223		$	165.13
Granted		121,896			136.22
Vested		(132,010	)		163.85
Forfeited		(3,623	)		152.21
Unvested, December 31, 2023		216,486		$	149.68

The weighted average grant-date fair value per unit of RSU awards granted was $136.22, $140.37 and $208.67 during the years ended December 31, 2023, 2022 and 2021, respectively. The grant date fair value of RSUs that vested during the year was $21.6 million for the year ended December 31, 2023, $18.0 million for the year ended December 31, 2022 and $12.5 million for the year ended December 31, 2021. The fair value of RSUs as of their respective vesting dates was $18.6 million for the year ended December 31, 2023, $15.3 million for the year ended December 31, 2022 and $15.1 million for the year ended December 31, 2021.

The following table summarizes the activity related to restricted stock award (RSA) share based payment awards:


	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested, January 1, 2023		33,637		$	178.37
Granted		2,366			126.87
Vested		(18,456	)		178.82
Unvested, December 31, 2023		17,547		$	170.96

Schedule of Nonvested Performance-Based Units Activity

The following table summarizes the activity related to performance unit awards (PSU) share based payment awards:


	Number of Shares			Weighted- Average Grant-Date Fair Value
Unvested, January 1, 2023		227,866		$	185.57
Granted		84,448			165.72
Vested		(11,970	)		155.85
Forfeited		(91,791	)		170.96
Unvested, December 31, 2023		208,553		$	185.86

EMPLOYEE RETIREMENT PLANS (Tables)

12 Months Ended

Dec. 31, 2023

Defined Benefit Pension Plans And Defined Benefit Postretirement Plans [Abstract]

Information Relating to the Company's Plan

Information relating to the Company’s plan is as follows (in thousands):


	Year Ended December 31,
	2023			2022
Change in benefit obligation:
Benefit obligation, beginning of year	$	61,804		$	66,773
Service cost		951			1,287
Interest cost		2,898			1,383
Actuarial gain		(9,375	)		(7,639	)
Benefit payments		(2,015	)		—
Benefit obligation, end of year		54,263			61,804
Fair value of plan assets		—			—
Unfunded status of the plan, end of year	$	54,263		$	61,804
Current liability	$	2,014		$	2,014
Non-current liability	$	52,249		$	59,790

Components of Net Periodic Pension Cost

The components of net periodic pension cost were as follows (in thousands):


	Year Ended December 31,
	2023		2022		2021
Service cost	$	951	$	1,287	$	1,675
Interest cost		2,898		1,383		1,165
Amortization of prior service cost		815		1,119		1,099
Amortization of loss		480		1,487		4,936
Total net periodic benefit cost	$	5,144	$	5,276	$	8,875

Assumptions Used to Determine Benefit Obligation and Net Periodic Pension Cost

Assumptions used to determine the year end benefit obligation were as follows:


	Year Ended December 31,
	2023			2022
Discount rate		4.74	%		4.94	%
Rate of compensation increases		3.50	%		3.50	%

Assumptions used to determine the net periodic pension cost were as follows:


	Year Ended December 31,
	2023			2022			2021
Discount rate		4.94	%		2.16	%		1.54	%
Rate of compensation increases		3.50	%		3.50	%		3.50	%

Amounts to be Amortized from Accumulated Other Comprehensive Loss into Net Periodic Pension Cost in Next Fiscal Year

The estimated amounts to be amortized from accumulated other comprehensive loss into the net periodic pension cost in 2024 are as follows (in thousands):


Amortization of prior service cost	$	43
Amortization of loss		—
Total	$	43

Benefit Payments Expected to be Paid

Benefit payments, which reflect estimated future service, are currently expected to be paid as follows (in thousands):


Year	Projected Benefits
2024	$	2,014
2025		5,097
2026		6,141
2027		6,489
2028		6,489
2029-2033		34,503
Thereafter		14,855

CONCENTRATION OF RISK (Tables)

12 Months Ended

Dec. 31, 2023

Risks and Uncertainties [Abstract]

Revenues and Accounts Receivable From Our Largest Customers

Revenues and accounts receivable from the Company's largest customers for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands):


	2023			2022			2021
Customer	% of Total Revenue	Accounts Receivable		% of Total Revenue	Accounts Receivable		% of Total Revenue	Accounts Receivable
A	36%	$	38,105	41%	$	11,425	44%	$	10,850
B	23%		30,142	25%		24,440	26%		45,867
C	17%		38,529	16%		22,291	14%		18,557

Revenues by Geographic Area

Revenues by geographic area are as follows (in thousands):


	Year Ended December 31,
Country	2023		2022		2021
South Korea	$	322,509	$	360,640	$	334,835
China		229,727		230,582		192,079
Japan		6,971		5,579		7,358
Other non-U.S. locations		4,411		3,829		3,137
Total non-U.S. locations		563,618		600,630		537,409
United States		12,811		15,989		16,116
Total revenue	$	576,429	$	616,619	$	553,525

Long-Lived Assets (Net) by Geographic Area

Property and equipment, net by geographic area are as follows (in thousands):


	December 31,
Country	2023		2022
United States	$	118,250	$	117,255
Ireland		42,203		20,270
Other		14,697		5,920
Total long-lived assets	$	175,150	$	143,445

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Components of Income (Loss) before Income Taxes

The components of income before income taxes are as follows (in thousands):


	Year ended December 31,
	2023		2022		2021
United States	$	71,514	$	77,205	$	60,066
Foreign		173,657		191,025		168,181
Income before income taxes	$	245,171	$	268,230	$	228,247

Components of Income Tax Expense

The components of the income tax expense are as follows (in thousands):


	Year ended December 31,
	2023			2022			2021
Current income tax (expense) benefit:
Federal	$	(15,848	)	$	(51,980	)	$	(16,433	)
State		(3,048	)		(1,833	)		(641	)
Foreign		(27,030	)		(31,302	)		(25,212	)
		(45,926	)		(85,115	)		(42,286	)
Deferred income tax (expense) benefit:
Federal		(460	)		25,916			(844	)
State		3,936			1,216			(734	)
Foreign		290			(186	)		(170	)
		3,766			26,946			(1,748	)
Income tax expense	$	(42,160	)	$	(58,169	)	$	(44,034	)

Reconciliation of the Statutory U.S. Federal Tax Rate to the Effective Tax Rate

Reconciliation of the statutory U.S. federal tax rate to the Company's effective tax rate is as follows:


	Year ended December 31,
	2023			2022			2021
Statutory U.S. federal income tax rate		21.0	%		21.0	%		21.0	%
Effect of foreign operations		(4.0	)		(4.9	)		(5.0	)
U.S. International Tax (Sub F, GILTI, FDII)		2.9			4.2			2.1
Research tax credits		(2.4	)		(1.9	)		(1.4	)
Redetermination of foreign tax credit utilization		(2.0	)		—			—
Nondeductible employee compensation		1.7			1.9			3.0
State income taxes, net of federal benefit		(0.2	)		0.1			0.2
Stock based compensation		0.1			0.2			(0.3	)
Accruals and reserves		—			—			(0.8	)
Other		0.1			1.1			0.5
Effective tax rate		17.2	%		21.7	%		19.3	%

Tax Loss and Tax Credit Carryforwards

The following table summarizes Company tax credit carry forwards for tax return purposes as of December 31, 2023 (in thousands):


	Tax Benefit		Expiration Date
Tax credit carry forwards:
State research tax credits	$	8,752	2034-2038
Foreign tax credits	$	186	2031
Total credit carry forwards	$	8,938

Significant Components of Deferred Tax Assets and Liabilities

Significant components of the Company's net deferred tax assets and liabilities are as follows (in thousands):


	December 31,
	2023			2022
Deferred tax asset:
Capitalized research expenditures	$	39,459		$	38,485
Retirement plan		12,555			13,495
Tax credit carry forwards		8,938			8,100
Accruals and reserves		7,180			6,944
Lease Liabilities		6,671			7,230
Deferred revenue		1,741			2,077
Stock-based compensation		1,498			1,454
Other		1,362			3,400
		79,404			81,185
Valuation allowance		(9,551	)		(11,087	)
Deferred tax assets		69,853			70,098
Deferred tax liability:
Lease Assets		(6,302	)		(6,944	)
Acquisition Goodwill		(1,549	)		(1,283	)
Other		(2,894	)		(3,710	)
Deferred tax liabilities		(10,745	)		(11,937	)
Net deferred tax assets	$	59,108		$	58,161

REVENUE RECOGNITION (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Assets and Liabilities Associated with Contracts from Customers

The following table provides information about assets and liabilities associated with the Company's contracts from customers (in thousands):


	As of December 31, 2023
Accounts receivable	$	139,850
Short-term unbilled receivables		21,084
Short-term contract assets		2,698
Long-term unbilled receivables		9,074
Long-term contract assets		9,278
Short-term deferred revenue		47,713
Long-term deferred revenue		12,006

Summary of Significant Changes in Unbilled Receivables and Deferred Liabilities Balances

Significant changes in the assets and liabilities balances associated with the Company's contracts from customers for the years ended December 31, 2023 and 2022, are as follows (in thousands):


	Year Ended December 31, 2023
	Assets			Liabilities
Balance at December 31, 2022	$	38,457		$	(63,878	)
Revenue recognized that was previously included in deferred revenue, net		—			195,703
Increases due to cash received		—			(202,100	)
Cumulative catch-up adjustment arising from changes in estimates of transaction price, net		—			10,556
Unbilled receivables recorded, net		41,659			—
Contract assets recorded, net		(2,407	)		—
Transferred to receivables from unbilled receivables		(35,575	)		—
Net change		3,677			4,159
Balance at December 31, 2023	$	42,134		$	(59,719	)

	Year Ended December 31, 2022
	Assets			Liabilities
Balance at December 31, 2021	$	8,127		$	(157,081	)
Revenue recognized that was previously included in deferred revenue, net		—			239,608
Increases due to cash received		—			(176,667	)
Cumulative catch-up adjustment arising from changes in estimates of transaction price, net		—			30,262
Unbilled receivables recorded, net		15,946			—
Contract assets recorded, net		14,384			—
Net change		30,330			93,203
Balance at December 31, 2022	$	38,457		$	(63,878	)

NET INCOME PER COMMON SHARE (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The following table is a reconciliation of net income and the shares used in calculating basic and diluted net income per common share for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share data):


	Year Ended December 31,
	2023			2022			2021
Numerator:
Net income	$	203,011		$	210,061		$	184,213
Adjustment for Basic EPS:
Earnings allocated to unvested shareholders		(993	)		(1,215	)		(1,137	)
Adjusted net income	$	202,018		$	208,846		$	183,076
Denominator:
Weighted average common shares outstanding – Basic		47,559,669			47,390,352			47,296,447
Effect of dilutive shares:
Common stock equivalents arising from stock options and ESPP		2,173			2,340			1,010
Restricted stock awards and units and performance units		60,921			75,815			67,978
Weighted average common shares outstanding – Diluted		47,622,763			47,468,507			47,365,435
Net income per common share:
Basic	$	4.25		$	4.41		$	3.87
Diluted	$	4.24		$	4.40		$	3.87

BUSINESS - Additional Information (Details)	Dec. 31, 2023 Patent
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of patents issued and pending application	6,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Jun. 28, 2016	Jul. 23, 2012
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturity period	three months or less
Allowance for doubtful accounts	$ 166,000	$ 279,000
Goodwill impairment loss	$ 0
Recognized income tax positions measured at likelihood of realization description	Recognized income tax positions are measured at the largest amount of which the likelihood of realization is greater than 50%
FUJIFILM [Member]
Summary Of Significant Accounting Policies [Line Items]
Amortization period of acquired intangible assets (in years)	10 years
Visionox Hefei Technology [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional agreement duration	5 years
Patents [Member] \| FUJIFILM [Member]
Summary Of Significant Accounting Policies [Line Items]
OLED patents useful life				10 years
Patents [Member] \| BASF [Member]
Summary Of Significant Accounting Policies [Line Items]
OLED patents useful life	10 years		10 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Recognized income tax positions measured at percentage of likelihood of realization	50.00%
Minimum [Member] \| Other Intangible Assets [Member] \| Adesis, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Amortization period of acquired intangible assets (in years)	10 years
Maximum [Member] \| Other Intangible Assets [Member] \| Adesis, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Amortization period of acquired intangible assets (in years)	15 years
Building [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (in years)	30 years
Building Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (in years)	15 years
Office, Lab Equipment and Furniture and Fixtures [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (in years)	3 years
Office, Lab Equipment and Furniture and Fixtures [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (in years)	7 years
Computer Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life (in years)	3 years

CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Cash, Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash And Cash Equivalents [Line Items]
Cash Equivalents, at Carrying Value	$ 91,985	$ 93,430
Cash Equivalents, Gross Unrealized Gains	0	0
Cash Equivalents, Gross Unrealized Losses	0	0
Cash and Cash Equivalents, Fair Value Disclosure	91,985	93,430
Cash Accounts in Banking Institutions [Member]
Cash And Cash Equivalents [Line Items]
Cash Equivalents, at Carrying Value	91,717	86,268
Cash Equivalents, Gross Unrealized Gains	0	0
Cash Equivalents, Gross Unrealized Losses	0	0
Cash and Cash Equivalents, Fair Value Disclosure	91,717	86,268
Money Market Accounts [Member]
Cash And Cash Equivalents [Line Items]
Cash Equivalents, at Carrying Value	268	7,162
Cash Equivalents, Gross Unrealized Gains	0	0
Cash Equivalents, Gross Unrealized Losses	0	0
Cash and Cash Equivalents, Fair Value Disclosure	$ 268	$ 7,162

CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Securities, Fair Value Disclosure		$ 4,000
Short-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	$ 422,532	490,170
Available-for-sale Securities, Gross Unrealized Gains	304	32
Available-for-sale Securities, Gross Unrealized Losses	(699)	(5,857)
Available-for-sale Securities, Fair Value Disclosure	422,137	484,345
Long-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	284,053	249,943
Available-for-sale Securities, Gross Unrealized Gains	1,457	52
Available-for-sale Securities, Gross Unrealized Losses	(8)	(2,180)
Available-for-sale Securities, Fair Value Disclosure	285,502	247,815
Corporate Bonds [Member] \| Short-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	1,763	150,698
Available-for-sale Securities, Gross Unrealized Gains	1	0
Available-for-sale Securities, Gross Unrealized Losses	(5)	(910)
Available-for-sale Securities, Fair Value Disclosure	1,759	149,788
Corporate Bonds [Member] \| Long-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis		2,479
Available-for-sale Securities, Gross Unrealized Gains		0
Available-for-sale Securities, Gross Unrealized Losses		(28)
Available-for-sale Securities, Fair Value Disclosure		2,451
U.S. Government Bonds [Member] \| Short-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	420,769	339,472
Available-for-sale Securities, Gross Unrealized Gains	303	32
Available-for-sale Securities, Gross Unrealized Losses	(694)	(4,947)
Available-for-sale Securities, Fair Value Disclosure	420,378	334,557
U.S. Government Bonds [Member] \| Long-term Investments [Member]
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis	284,053	247,464
Available-for-sale Securities, Gross Unrealized Gains	1,457	52
Available-for-sale Securities, Gross Unrealized Losses	(8)	(2,152)
Available-for-sale Securities, Fair Value Disclosure	$ 285,502	$ 245,364

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3

+ Details

CASH, CASH EQUIVALENTS AND INVESTMENTS - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Investment	Dec. 31, 2023 USD ($)	Dec. 31, 2021 Investment
Cash and Cash Equivalents [Line Items]
Number of minority investments \| Investment			4
Minority investment, carrying value	$ 12.0	$ 14.0
Number Of Convertible Note Investments \| Investment	2
Available-for-sale Securities, Fair Value Disclosure	$ 4.0
Impairment in minority investment	$ 3.0

FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 91,985	$ 93,430
Short-term Corporate bonds	422,137	484,345
Short-term U.S. Government bonds	2,698
Long-term U.S. Government bonds	299,548	259,861
Fair Value, Measurements, Recurring [Member] \| Reported Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	268	7,162
Short-term Corporate bonds	1,759	149,788
Short-term U.S. Government bonds	420,378	334,557
Long-term Corporate bonds		2,451
Long-term U.S. Government bonds	285,502	245,364
Fair Value, Measurements, Recurring [Member] \| Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	268	7,162
Short-term Corporate bonds	1,759	149,788
Short-term U.S. Government bonds	420,378	334,557
Long-term Corporate bonds		2,451
Long-term U.S. Government bonds	$ 285,502	$ 245,364

FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Credit losses on debt investments	$ 0	$ 0

INVENTORY - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 113,400	$ 115,448
Work-in-process	9,433	7,626
Finished goods	52,962	60,146
Inventory	$ 175,795	$ 183,220

INVENTORY - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Change in inventory reserve	$ 8.5	$ 3.6	$ 3.6

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 319,058	$ 260,563
Less: Accumulated depreciation	(143,908)	(117,118)
Property and equipment, net	175,150	143,445
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,230	2,642
Building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	116,903	99,586
Office and lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	148,465	129,697
Furniture, fixtures and computer related assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	18,970	18,071
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 22,490	$ 10,567

PROPERTY AND EQUIPMENT - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 27,409	$ 24,815	$ 19,968
Increase in property and equipment	$ 59,792	$ 42,497	$ 43,161
Property Available for Operating Lease [Member]
Property, Plant and Equipment [Line Items]
Descripion of Property Available for Operating Lease	The increase in property and equipment, net for the year ended December 31, 2023 is primarily due to the purchases of two previously leased facilities for an aggregate cost of $23.4 million
Increase in property and equipment	$ 23,400

GOODWILL AND INTANGIBLE ASSETS - Schedule of Acquired Technology (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

^[1]

Dec. 31, 2022

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

$ 277,175

$ 228,053

Less: Accumulated amortization

(186,850)

(189,671)

Acquired technology, net

90,325

38,382

PD LD, Inc [Member]

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

0

1,481

Motorola [Member]

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

0

15,909

Merck KGaA[Member]

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

66,012

0

BASF [Member]

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

95,989

FUJIFILM [Member]

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

109,462

Other [Member]

Finite-Lived Intangible Assets [Line Items]

Acquired technology, gross

$ 5,712

$ 5,212

[1]	During the year ended December 31, 2023, the gross value and accumulated amortization associated with the PD-LD, Inc. and Motorola patent portfolios have been removed from the table as the underlying patents have reached the end of their useful lives.

GOODWILL AND INTANGIBLE ASSETS - Acquired Technology - Additional Information (Details) € in Millions					12 Months Ended
	Apr. 28, 2023 USD ($) Board_member	Jun. 28, 2016 USD ($) Patent	Jun. 28, 2016 EUR (€) Patent	Jul. 23, 2012 USD ($) Patent	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2029 USD ($)	Dec. 31, 2028 USD ($)	Dec. 31, 2027 USD ($)	Dec. 31, 2026 USD ($)	Apr. 30, 2023 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets					$ 15,993,000	$ 17,459,000	$ 21,994,000
Future amortization expense, 2023					16,800,000
Future amortization expense, 2024					16,800,000
Future amortization expense, 2025					16,800,000
Future amortization expense, 2026											$ 12,000,000
Future amortization expense, 2027									$ 7.2	$ 7.2
Future amortization expense, thereafter								$ 30,300,000
Patent Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets					$ 14,600,000	$ 16,000,000	$ 20,600,000
Patents [Member] \| FUJIFILM [Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents acquired (more than) \| Patent				1,200
Assigned value of acquired intangible assets				$ 105,000,000
Cash paid for OLED patents				$ 4,500,000
OLED patents useful life				10 years
Patents [Member] \| BASF [Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents acquired (more than) \| Patent		500	500
Assigned value of acquired intangible assets		$ 95,800,000	€ 86.8
Acquisition Costs, Period Cost		95,800,000	€ 86.8
Cash paid for OLED patents		$ 217,000,000
OLED patents useful life		10 years			10 years
Patents [Member] \| Merck KGaA[Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents acquired (more than) \| Board_member	550
Assigned value of acquired intangible assets	$ 66,000,000
Cash paid for OLED patents												$ 66,000,000
OLED patents useful life												10 years

GOODWILL AND INTANGIBLE ASSETS - Other Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2027	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Other intangible assets	$ 16,800,000
Goodwill	15,535,000	$ 15,535,000
Adesis, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets	17,288,000
Amortization expense related to other intangible assets	1,400,000	$ 1,400,000	$ 1,400,000
Future amortization expense of other intangible assets, fiscal year 2024	1,400,000
Future amortization expense of other intangible assets, fiscal year 2026						$ 1,400,000
Future amortization expense of other intangible assets, fiscal year 2025					$ 1,400,000
Future amortization expense of other intangible assets, fiscal year 2027				$ 1,300,000
Future amortization expense of other intangible assets, fiscal year 2028				422,000			$ 1,400,000
Future amortization expense of other intangible assets, thereafter				$ 1,000,000
Goodwill	15,500,000
Adesis, Inc. [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets	$ 10,520,000
Amortization period of acquired intangible assets (in years)	11 years 6 months
Adesis, Inc. [Member] \| Internally-developed IP, Processes and Recipes [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets	$ 4,820,000
Amortization period of acquired intangible assets (in years)	15 years
Adesis, Inc. [Member] \| Trade Name/Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets	$ 1,500,000
Amortization period of acquired intangible assets (in years)	10 years
FUJIFILM [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period of acquired intangible assets (in years)	10 years

GOODWILL AND INTANGIBLE ASSETS - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 16,800
Accumulated Amortization	(10,414)	$ (8,989)
Net Carrying Amount	6,874	$ 8,247
Adesis, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	17,288
Accumulated Amortization	(10,414)
Net Carrying Amount	6,874
Customer Relationships [Member] \| Adesis, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,520
Accumulated Amortization	(6,801)
Net Carrying Amount	3,719
Developed IP, Processes and Recipes [Member] \| Adesis, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,820
Accumulated Amortization	(2,388)
Net Carrying Amount	2,432
Trade Name/Trademarks [Member] \| Adesis, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,500
Accumulated Amortization	(1,118)
Net Carrying Amount	382
Other Intangible Assets [Member] \| Adesis, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	448
Accumulated Amortization	(107)
Net Carrying Amount	$ 341

OTHER ASSETS - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Assets [Abstract]
Long-term taxes receivable	$ 60,146	$ 63,915
Right-of-use assets	24,910	31,486
Long-term unbilled receivables	$ 9,074	$ 0
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Long-term contract assets	$ 9,278	$ 11,651
Other Long-Term Investments	1,881	2,687
Other Assets, Total	$ 105,289	$ 109,739

LEASES- Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lessee Lease Description [Line Items]
Operating lease description	As of December 31, 2023, the Company did not have any finance leases and no additional operating leases that have not yet commenced.
Operating lease cost	$ 4,639	$ 4,436	$ 3,637
Operating lease, option to extend			true
Minimum [Member]
Lessee Lease Description [Line Items]
Operating leases remaining term	3 years
Maximum [Member]
Lessee Lease Description [Line Items]
Operating leases remaining term	8 years

LEASES - Summary of Operating Lease Cost and Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease cost	$ 4,639	$ 4,436	$ 3,637
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	$ 1,072	$ 4,750	$ 26,174

LEASES - Schedule Of Operating Lease Right of Use Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Right-of-use assets	$ 24,910	$ 31,486
Short-term lease liabilities	$ 3,533	$ 3,737
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Long-term lease liabilities	$ 22,855	$ 29,039
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent

LEASES - Schedule of Weighted Average Assumptions Used to Compute Right-of-use Assets and Lease Liabilities (Details)	Dec. 31, 2023
Leases [Abstract]
Weighted average remaining lease term (in years)	6 years 8 months 12 days
Weighted average discount rate	3.70%

LEASES - Schedule of Undiscounted Future Minimum Lease Payments Having Non-cancelable Lease Terms (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Lessee Lease Description [Line Items]
2024	$ 4,267
2025	4,401
2026	4,321
2027	4,323
2028	3,996
Thereafter	8,083
Total lease payments	29,391
Less: imputed interest	(3,003)
Present value of lease payments	$ 26,388

ACCRUED EXPENSES - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Compensation	$ 29,456	$ 31,751
PPG Industries, Inc. agreement	11,962	9,864
Consulting	2,121	910
Professional Fees	1,124	906
Research and development agreements	822	662
Royalties	647	877
Other	5,948	6,032
Accrued Expenses	$ 52,080	$ 51,002

RESEARCH AND LICENSE AGREEMENTS WITH ACADEMIC PARTNERS- Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty expense	$ 647	$ 877	$ 691
1997 Amended License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty expense	575,000	853,000	691,000
2006 Research Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum obligation	2,000
Research and development expense incurred	$ 1,100	$ 905,000	$ 1,300

OTHER LIABILITIES - Summary of Other liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Long-term taxes payable	$ 15,749	$ 14,592
Long-term lease liabilities	$ 22,855	$ 29,039
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Other long-term liabilities	$ 54	$ 54
Other Liabilities	$ 38,658	$ 43,685

EQUITY AND CASH COMPENSATION UNDER THE PPG AGREEMENTS - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Long-term Purchase Commitment [Line Items]
Percent of services payable in cash or shares	50.00%
Issuance of common stock in connection with materials and license agreements (in shares)	0
Charges to expense for cash portion of reimbursement of expenses	$ 9.1	$ 7.3	$ 3.6
New OLED Materials Agreement and OLED Materials Agreement [Member] \| Weighted Average
Long-term Purchase Commitment [Line Items]
Minimum average closing price of common stock (in dollars per share)	$ 20

SHAREHOLDERS' EQUITY - Additional Information (Details) $ / shares in Units, $ in Millions		12 Months Ended
	Feb. 20, 2024 $ / shares	Dec. 31, 2023 USD ($) Board_member $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 $ / shares
Class Of Stock [Line Items]
Preferred Stock, shares authorized ( in shares)		5,000,000	5,000,000
Preferred Stock, par value (in dollars per share) \| $ / shares		$ 0.01	$ 0.01
Number of board members elected by class A shareholders \| Board_member		2
Common Stock, shares authorized (in shares)		200,000,000	200,000,000
Common Stock, par value (in dollars per share) \| $ / shares		$ 0.01	$ 0.01
Common Stock, shares issued (in shares)		48,731,026	49,136,030
Common Stock, shares outstanding (in shares)		47,365,378	47,770,382
Treasury stock repurchased shares		0	0
Common stock dividends declared per share \| $ / shares		$ 1.4	$ 1.2	$ 0.8
Common stock dividends paid per share \| $ / shares		$ 1.4
Common stock dividends paid \| $		$ 66.7
Subsequent Event [Member]
Class Of Stock [Line Items]
Common stock dividends declared per share \| $ / shares	$ 0.4
Dividend payable date	Mar. 29, 2024
Dividend record date	Mar. 15, 2024
Series A Nonconvertible Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred Stock, shares issued (in shares)		200,000	200,000
Preferred Stock, liquidation value per share (in dollars per share) \| $ / shares		$ 7.5	$ 7.5
Preferred stock voting rights		Holders of the Series A shares are entitled to one vote per share on matters which shareholders are generally entitled to vote.
Preferred Stock, shares outstanding (in shares)		200,000	200,000
Series A Nonconvertible Preferred Stock [Member] \| One Nine Nine Five [Member]
Class Of Stock [Line Items]
Preferred Stock, shares issued (in shares)		200,000

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

BALANCE

$ 1,275,369

$ 1,099,914

$ 912,714

Reclassification to net income

1,000

2,000

4,700

Other comprehensive loss

17,366

(217)

17,784

BALANCE

1,447,226

1,275,369

1,099,914

Unrealized gain (loss) on available-for-sale securities [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

BALANCE

(7,887)

(142)

91

Other comprehensive gain (loss) before reclassification

8,745

(7,745)

(233)

Plan amendment cost

0

Reclassification to net income

^[1]

0

Other comprehensive loss

8,745

(7,745)

(233)

BALANCE

858

(7,887)

(142)

Net unrealized gain (loss) on retirement plan [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

BALANCE

^[2]

(10,011)

(18,019)

(36,075)

Other comprehensive gain (loss) before reclassification

^[2]

7,207

5,971

13,620

Plan amendment cost

^[2]

(283)

Reclassification to net income

^[1],[2]

996

2,037

4,719

Other comprehensive loss

^[2]

8,203

8,008

18,056

BALANCE

^[2]

(1,808)

(10,011)

(18,019)

Change in cumulative foreign currency translation adjustment [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

BALANCE

(554)

(74)

(35)

Other comprehensive gain (loss) before reclassification

418

(480)

(39)

Plan amendment cost

0

Reclassification to net income

^[1]

0

Other comprehensive loss

418

(480)

(39)

BALANCE

(136)

(554)

(74)

Accumulated Other Comprehensive Loss [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

BALANCE

(18,452)

(18,235)

(36,019)

Other comprehensive gain (loss) before reclassification

16,370

(2,254)

13,348

Plan amendment cost

(283)

Reclassification to net income

^[1]

996

2,037

4,719

Other comprehensive loss

17,366

(217)

17,784

BALANCE

$ (1,086)

$ (18,452)

$ (18,235)

[1]	The Company reclassified amortization of prior service cost, actuarial loss and plan amendment cost for its retirement plan from accumulated other comprehensive loss to net income of $1.0 million, $2.0 million and $4.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.
[2]	Refer to Note 17: Employee Retirement Plans

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Parenthetical) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Reclassification to net income	$ 1.0	$ 2.0	$ 4.7

STOCK-BASED COMPENSATION - Equity Compensation Plan - Additional Information (Details) - Equity Compensation Plan [Member]	12 Months Ended
	Dec. 31, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)	1,519,235
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration term (in years)	10 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

STOCK-BASED COMPENSATION - Equity Instruments Other Than Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested, January 1, 2023	230,223
Number of Shares, Granted	121,896
Number of Shares, Vested	(132,010)
Number of Shares, Forfeited	(3,623)
Number of Shares, Unvested, December 31, 2023	216,486	230,223
Weighted-Average Grant-Date Fair Value, Unvested, January 1, 2023	$ 165.13
Weighted-Average Grant-Date Fair Value, Granted	136.22	$ 140.37	$ 208.67
Weighted-Average Grant-Date Fair Value, Vested	163.85
Weighted-Average Grant-Date Fair Value, Forfeited	152.21
Weighted-Average Grant-Date Fair Value, Unvested, December 31, 2023	$ 149.68	$ 165.13
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested, January 1, 2023	33,637
Number of Shares, Granted	2,366
Number of Shares, Vested	(18,456)
Number of Shares, Unvested, December 31, 2023	17,547	33,637
Weighted-Average Grant-Date Fair Value, Unvested, January 1, 2023	$ 178.37
Weighted-Average Grant-Date Fair Value, Granted	126.87	$ 148.35	172.95
Weighted-Average Grant-Date Fair Value, Vested	178.82
Weighted-Average Grant-Date Fair Value, Unvested, December 31, 2023	$ 170.96	$ 178.37
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Unvested, January 1, 2023	227,866
Number of Shares, Granted	84,448
Number of Shares, Vested	(11,970)
Number of Shares, Forfeited	(91,791)
Number of Shares, Unvested, December 31, 2023	208,553	227,866
Weighted-Average Grant-Date Fair Value, Unvested, January 1, 2023	$ 185.57
Weighted-Average Grant-Date Fair Value, Granted	165.72	$ 186.66	$ 214.7
Weighted-Average Grant-Date Fair Value, Vested	155.85
Weighted-Average Grant-Date Fair Value, Forfeited	170.96
Weighted-Average Grant-Date Fair Value, Unvested, December 31, 2023	$ 185.86	$ 185.57

STOCK-BASED COMPENSATION - Equity Instruments Other Than Options - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of shares withheld for tax withholding obligations	$ 8,206,000	$ 9,209,000	$ 14,949,000
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards and units vesting terms	1 year
Fair value of shares issued	$ 1,500,000	$ 1,300,000	$ 1,200,000
Shares issued (in shares)	13,016	8,784	5,412
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value of RSU awards granted (in dollars per share)	$ 136.22	$ 140.37	$ 208.67
Fair value granted as of the respective vesting dates	$ 21,600,000	$ 18,000,000	$ 12,500,000
Fair value as of the respective vesting dates	$ 18,600,000	15,300,000	15,100,000
Grants in period (shares)	121,896
Restricted Stock Units (RSUs) [Member] \| Research and Development Expense [Member] \| Non Employee Members of Scientific Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 248,000	$ 234,000	$ 220,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value of RSU awards granted (in dollars per share)	$ 126.87	$ 148.35	$ 172.95
Fair value granted as of the respective vesting dates	$ 3,300,000	$ 8,300,000	$ 9,300,000
Fair value as of the respective vesting dates	$ 2,600,000	$ 6,500,000	$ 20,000,000
Shares withheld for employee taxes (shares)	53,162	54,856	67,798
Shares withheld for employee taxes	$ 7,400,000	$ 8,400,000	$ 14,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 21,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 9 months 18 days
Grants in period (shares)	2,366
Unrecognized compensation expense related to performance unit awards	$ 21,700,000
Restricted Stock [Member] \| Selling, General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	9,500,000	14,300,000	15,400,000
Restricted Stock [Member] \| Manufacturing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	1,900,000	2,200,000	2,500,000
Restricted Stock [Member] \| Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 5,800,000	$ 6,100,000	$ 5,200,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant-date fair value of RSU awards granted (in dollars per share)	$ 165.72	$ 186.66	$ 214.7
Fair value granted as of the respective vesting dates	$ 1,900,000	$ 1,900,000	$ 1,100,000
Fair value as of the respective vesting dates	1,700,000	$ 1,800,000	$ 2,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 12,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 11 months 23 days
Grants in period (shares)	84,448
Shares withheld for tax withholding obligations (in shares)	5,350	5,082	3,881
Fair value of shares withheld for tax withholding obligations	$ 775,000	$ 826,000	$ 875,000
Unrecognized compensation expense related to performance unit awards	$ 12,900,000
Performance Shares [Member] \| Incremental Performance Based [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (shares)	84,448	100,621	77,086
Performance Shares [Member] \| Performance-Based Vesting Requirement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (shares)	63,335	75,465	42,291
Performance Shares [Member] \| Market-Based Vesting Requirement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (shares)	21,113	25,156	34,795
Performance Shares [Member] \| Company Performance-Based Vesting Requirement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (shares)	0	1,268	0
Performance Shares [Member] \| Selling, General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 2,600,000	$ 2,800,000	$ 8,000,000
Performance Shares [Member] \| Manufacturing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	770,000	940,000	1,300,000
Performance Shares [Member] \| Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 1,200,000	$ 1,500,000	$ 2,100,000

STOCK-BASED COMPENSATION - Employee Stock Purchase Plan - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 25, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from common stock issued	$ 2,554,000	$ 2,043,000	$ 1,907,000
Employee Stock Purchase Plan (ESPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Stock Purchase Plan ESPP Purchase Period1	3 months
Reserved for issuance (in shares)				1,000,000
Percentage of market value (in hundredths)	85.00%
Maximum allocation of base compensation (in hundredths)	10.00%
Maximum shares per purchase date (in shares)	12,500
Maximum value per calendar year, per employee	$ 25,000
Common stock issued (in shares)	17,513	17,057	9,156
Proceeds from common stock issued	$ 2,000,000	$ 1,600,000	$ 1,500,000
Employee Stock Purchase Plan (ESPP) [Member] \| Selling, General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Charges to expense	136,000	107,000	93,000
Employee Stock Purchase Plan (ESPP) [Member] \| Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Charges to expense	167,000	141,000	119,000
Employee Stock Purchase Plan (ESPP) [Member] \| Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Charges to expense	$ 240,000	$ 224,000	$ 188,000

STOCK-BASED COMPENSATION - Deferred Compensation Arrangement - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Non-Employee Members of Scientific Advisory Board [Member]
Deferred Compensation Arrangement with Employees and Non-Employees, Share-Based Payments [Line Items]
Shares issued (in shares)	2,366	2,024
Members of Scientific Advisory Board [Member]
Deferred Compensation Arrangement with Employees and Non-Employees, Share-Based Payments [Line Items]
Fair value of shares issued	$ 300,000	$ 300,000

EMPLOYEE RETIREMENT PLANS - Additional Information (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) Denominator Multiple Participant	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Maximum contribution percentage (in hundredths)	90.00%
Matching contribution limit (in hundredths)	3.00%
Contributions to the 401(k) Plan	$ 1,500,000	$ 1,400,000	$ 1,300,000
Benefit Payments	(2,015,000)	0
Prior service cost expected to be amortized in next fiscal year	43,000
Actuarial (gain) loss	$ 9,375,000	7,639,000
Supplemental Executive Retirement Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of participants \| Participant	8
Factor used to determine annual base salary \| Multiple	12
Annual base salary period (in months)			24 months
Minimum period of service (in years)	20 years
Benefit percentage, tier one (in hundredths)	50.00%
Benefit percentage, tier two (in hundredths)	25.00%
Benefit percentage, tier three (in hundredths)	15.00%
Minimum period of service for prorated benefit (in years)	15 years
Factor used to determine prorated benefit \| Denominator	20
Installment period (in years)	10 years
Benefit percentage for special participants (in hundredths)	50.00%
Initial prior service cost for retirement plan	$ 1,900,000
Benefit Payments	2,000,000
Prior service cost expected to be amortized in next fiscal year	43,000
Accumulated benefit obligation	$ 52,500,000	59,500,000
Defined benefit plan threshold of benefit obligation at which actuarial losses are amortized (in hundredths)	10.00%
Actuarial (gain) loss	$ 9,400,000	$ 7,600,000

EMPLOYEE RETIREMENT PLANS - Information Relating to the Company's Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Change in benefit obligation:
Benefit obligation, beginning of year	$ 61,804	$ 66,773
Service cost	951	1,287
Interest cost	$ 2,898	$ 1,383
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Non-current liability	Non-current liability
Actuarial gain	$ (9,375)	$ (7,639)
Benefit Payments	(2,015)	0
Benefit obligation, end of year	54,263	61,804
Fair value of plan assets	0	0
Unfunded status of the plan, end of year	(54,263)	(61,804)
Current liability	2,014	2,014
Non-current liability	$ 52,249	$ 59,790

EMPLOYEE RETIREMENT PLANS - Components of Net Periodic Pension Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Components of net periodic pension cost [Abstract]
Service cost	$ 951	$ 1,287
Interest cost	$ 2,898	$ 1,383
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Liability, Defined Benefit Plan, Noncurrent	Liability, Defined Benefit Plan, Noncurrent	Liability, Defined Benefit Plan, Noncurrent
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Liability, Defined Benefit Plan, Noncurrent	Liability, Defined Benefit Plan, Noncurrent	Liability, Defined Benefit Plan, Noncurrent
Supplemental Executive Retirement Plan [Member]
Components of net periodic pension cost [Abstract]
Service cost	$ 951	$ 1,287	$ 1,675
Interest cost	2,898	1,383	1,165
Amortization of prior service cost	815	1,119	1,099
Amortization of loss	480	1,487	4,936
Total net periodic benefit cost	$ 5,144	$ 5,276	$ 8,875

EMPLOYEE RETIREMENT PLANS - Assumptions Used to Determine Benefit Obligation (Details)	Dec. 31, 2023	Dec. 31, 2022
Assumptions used to determine the year end benefit obligation [Abstract]
Discount rate	4.74%	4.94%
Rate of compensation increases	3.50%	3.50%

EMPLOYEE RETIREMENT PLANS - Assumptions Used to Determine Net Periodic Pension Cost (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assumptions used to determine the net periodic pension cost [Abstract]
Discount rate	4.94%	2.16%	1.54%
Rate of compensation increases	3.50%	3.50%	3.50%

EMPLOYEE RETIREMENT PLANS - Amounts to be Amortized from Accumulated Other Comprehensive Loss into Net Periodic Pension Cost in Next Fiscal Year (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Estimated amounts to be amortized from accumulated other comprehensive loss in next fiscal year [Abstract]
Amortization of prior service cost	$ 43
Amortization of loss	0
Total	$ 43

EMPLOYEE RETIREMENT PLANS - Benefit Payments Expected to be Paid (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Benefit payments currently expected to be paid [Abstract]
2024	$ 2,014
2025	5,097
2026	6,141
2027	6,489
2028	6,489
2029-2033	34,503
Thereafter	$ 14,855

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) $ in Millions	Dec. 31, 2023 USD ($) Multiple Employee ExecutiveOfficer	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Purchase commitments for inventory \| $	$ 29.8	$ 31.9	$ 25.7
Commitment With Executive Officers [Member]
Loss Contingencies [Line Items]
Number of executive officers under agreement \| ExecutiveOfficer	5
Number of employees under agreement \| Employee	13
Commitment With Senior Level Employees [Member]
Loss Contingencies [Line Items]
Multiple of sum of average annual base salary and bonus agreement terms	2
Commitment With Senior Level Employees [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Multiple of sum of average annual base salary and bonus agreement terms	2
Commitment With Senior Level Employees [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Multiple of sum of average annual base salary and bonus agreement terms	1

CONCENTRATION OF RISK - Revenues and Accounts Receivable From Our Largest Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Accounts Receivable	$ 139,850	$ 92,664
Major Customer A [Member] \| Total Revenue [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
% of Total Revenue	36.00%	41.00%	44.00%
Major Customer A [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable	$ 38,105	$ 11,425	$ 10,850
Major Customer B [Member] \| Total Revenue [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
% of Total Revenue	23.00%	25.00%	26.00%
Major Customer B [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable	$ 30,142	$ 24,440	$ 45,867
Major Customer C [Member] \| Total Revenue [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
% of Total Revenue	17.00%	16.00%	14.00%
Major Customer C [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable	$ 38,529	$ 22,291	$ 18,557

CONCENTRATION OF RISK - Additional Information (Details) - Supplier	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Number of suppliers from which chemical materials were purchased	1
Excluding North America [Member] \| Total Revenue [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage (less than 1% for contracts with U.S. government agencies)	98.00%	97.00%	97.00%

CONCENTRATION OF RISK - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Revenues	$ 576,429	$ 616,619	$ 553,525
South Korea [Member]
Concentration Risk [Line Items]
Revenues	322,509	360,640	334,835
China [Member]
Concentration Risk [Line Items]
Revenues	229,727	230,582	192,079
Japan [Member]
Concentration Risk [Line Items]
Revenues	6,971	5,579	7,358
Other Non-U.S. Locations [Member]
Concentration Risk [Line Items]
Revenues	4,411	3,829	3,137
Total Non-U.S. Locations [Member]
Concentration Risk [Line Items]
Revenues	563,618	600,630	537,409
United States [Member]
Concentration Risk [Line Items]
Revenues	$ 12,811	$ 15,989	$ 16,116

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

+ Details

CONCENTRATION OF RISK - Long-Lived Assets (Net) by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total long-lived assets	$ 175,150	$ 143,445
United States [Member]
Segment Reporting Information [Line Items]
Total long-lived assets	118,250	117,255
Ireland [Member]
Segment Reporting Information [Line Items]
Total long-lived assets	42,203	20,270
Other [Member]
Segment Reporting Information [Line Items]
Total long-lived assets	$ 14,697	$ 5,920

INCOME TAXES - Components of Income (Loss) before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Components of income before income taxes [Abstract]
United States	$ 71,514	$ 77,205	$ 60,066
Foreign	173,657	191,025	168,181
Income before income taxes	$ 245,171	$ 268,230	$ 228,247

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

INCOME TAXES - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current income tax (expense) benefit:
Federal	$ (15,848)	$ (51,980)	$ (16,433)
State	(3,048)	(1,833)	(641)
Foreign	(27,030)	(31,302)	(25,212)
Current income tax benefit (expense)	(45,926)	(85,115)	(42,286)
Deferred income tax (expense) benefit:
Federal	(460)	25,916	(844)
State	3,936	1,216	(734)
Foreign	(290)	(186)	(170)
Deferred income tax expense, gross	3,766	26,946	(1,748)
Income tax expense	$ (42,160)	$ (58,169)	$ (44,034)

INCOME TAXES - Reconciliation of the Statutory U.S. Federal Tax Rate to the Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	21.00%	21.00%	21.00%
Effect of foreign operations	(4.00%)	(4.90%)	(5.00%)
U.S. International Tax (Sub F, GILTI, FDII)	2.90%	4.20%	2.10%
Research tax credits	(2.40%)	(1.90%)	(1.40%)
Redetermination of foreign tax credit utilization	(2.00%)	0.00%	0.00%
Nondeductible employee compensation	1.70%	1.90%	3.00%
State income taxes, net of federal benefit	(0.20%)	0.10%	0.20%
Stock based compensation	0.10%	0.20%	(0.30%)
Accruals and reserves	0.00%	0.00%	(0.80%)
Other	0.10%	1.10%	0.50%
Effective tax rate	17.20%	21.70%	19.30%

INCOME TAXES - Tax Loss and Tax Credit Carryforwards (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Tax Credit And Operating Loss Carryforwards [Line Items]
Total credit carry forwards, Tax Benefit	$ 8,938
Foreign Tax Authority [Member]
Tax Credit And Operating Loss Carryforwards [Line Items]
Total credit carry forwards, Tax Benefit	$ 186
Tax credit carryforwards, Expiration Date	Dec. 31, 2031
Research Tax Credit [Member] \| State [Member]
Tax Credit And Operating Loss Carryforwards [Line Items]
Total credit carry forwards, Tax Benefit	$ 8,752
Research Tax Credit [Member] \| State [Member] \| Minimum [Member]
Tax Credit And Operating Loss Carryforwards [Line Items]
Tax credit carryforwards, Expiration Date	Dec. 31, 2034
Research Tax Credit [Member] \| State [Member] \| Maximum [Member]
Tax Credit And Operating Loss Carryforwards [Line Items]
Tax credit carryforwards, Expiration Date	Dec. 31, 2038

INCOME TAXES - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax asset:
Capitalized research expenditures	$ 39,459	$ 38,485
Retirement plan	12,555	13,495
Tax credit carry forwards	8,938	8,100
Accruals and reserves	7,180	6,944
Lease liabilities	6,671	7,230
Deferred revenue	1,741	2,077
Stock-based compensation	1,498	1,454
Other	1,362	3,400
Valuation allowance	(9,551)	(11,087)
Deferred Tax Assets, Gross	79,404	81,185
Deferred tax assets	69,853	70,098
Deferred tax liability:
Lease Assets	6,302	6,944
Acquisition Goodwill	(1,549)	(1,283)
Other	(2,894)	(3,710)
Deferred tax liabilities	(10,745)	(11,937)
Net deferred tax assets	$ 59,108	$ 58,161

INCOME TAXES - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Long-term asset	$ 105,289	$ 109,739
Current income tax expense	$ 27,030	31,302	$ 25,212
State and foreign income tax returns subject to examination period minimum (in years)	3 years
State and foreign income tax returns subject to examination period maximum (in years)	4 years
Korean Government [Member]
Income Taxes [Line Items]
Long-term asset	$ 0	3,000
South Korea [Member]
Income Taxes [Line Items]
Current income tax expense	14,900
Foreign exchange loss	732,000
Allocation of Withholding to Non-Korean Patents [Member]
Income Taxes [Line Items]
Long-term asset	60,100	60,900
Allocation of Withholding to Non-Korean Patents [Member] \| U.S.Federal Government [Member]
Income Taxes [Line Items]
Estimated settlement amounts due (refunds) from withholding taxes	$ 15,700	$ 14,600

REVENUE RECOGNITION - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Backlog associated with committed purchase orders from customers	$ 25,200
Contract with customer liability, transaction price	10,600	$ 30,300
Cumulative catch-up adjustment arising from changes in estimates of transaction price	$ 10,556	$ 30,262
Revenue from Contracts with Customers - ASU No. 2014-09 [Member]
Disaggregation Of Revenue [Line Items]
Percentage of revenue recorded from sales of materials	97.00%	97.00%	97.00%
Revenue from Contracts with Customers - ASU No. 2014-09 [Member] \| Adesis, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Percentage of revenue recorded from provision of services	3.00%	3.00%	3.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

REVENUE RECOGNITION - Schedule of Assets and Liabilities Associated with Contracts from Customers (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Accounts receivable	$ 139,850	$ 92,664
Short-term unbilled receivables	21,084
Short-term contract assets	2,698
Long-term unbilled receivables	9,074
Long-term contract assets	9,278
Short-term deferred revenue	47,713	45,599
Long-term deferred revenue	$ 12,006	$ 18,279

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

REVENUE RECOGNITION - Summary of Significant Changes in Unbilled Receivables and Deferred Liabilities Balances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Deferred Revenue (Increase) Decrease
Balance	$ (63,878)	$ (157,081)
Revenue recognized that was previously included in deferred revenue	195,703	239,608
Increases due to cash received	(202,100)	(176,667)
Cumulative catch-up adjustment arising from changes in estimates of transaction price	10,556	30,262
Net change	4,159	93,203
Balance	(59,719)	(63,878)
Unbilled Receivables Increase (Decrease)
Balance	38,457	8,127
Unbilled receivables recognized	41,659	15,946
Contract Assets Recorded	(2,407)	14,384
Transferred to receivables from unbilled receivables	(35,575)
Contract Assets Recorded	(2,407)	14,384
Net change	3,677	30,330
Balance	$ 42,134	$ 38,457

NET INCOME PER COMMON SHARE - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net income	$ 203,011	$ 210,061	$ 184,213
Adjustment for Basic EPS:
Earnings allocated to unvested shareholders	(993)	(1,215)	(1,137)
Adjusted net income	$ 202,018	$ 208,846	$ 183,076
Denominator:
Weighted average common shares outstanding – Basic	47,559,669	47,390,352	47,296,447
Effect of dilutive shares:
Common stock equivalents arising from stock options and ESPP	2,173	2,340	1,010
Restricted stock awards and units and performance units	60,921	75,815	67,978
Weighted average common shares outstanding – Diluted	47,622,763	47,468,507	47,365,435
Basic	$ 4.25	$ 4.41	$ 3.87
Diluted	$ 4.24	$ 4.4	$ 3.87

NET INCOME PER COMMON SHARE - Additional Information (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Antidilutive securities excluded from calculation of diluted EPS	36,345	122,843	0

QUARTERLY SUPPLEMENTAL FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 576,429	$ 616,619	$ 553,525
Net Income (Loss)	$ 203,011	$ 210,061	$ 184,213
Net income per common share:
Basic	$ 4.25	$ 4.41	$ 3.87
Diluted	$ 4.24	$ 4.4	$ 3.87

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

+ Details